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General introduction 
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Preeclampsia and HELLP syndrome 
Preeclampsia (PE) is defined as the de-novo development of hypertension (≥140/90 
mmHg) along with the de-novo proteinuria (≥ 300 mg/day proteinuria) after the 20th 
week of pregnancy [1]. The HELLP syndrome, a more severe form of this disorder, is 
defined on the basis of the acronyms of its symptoms (Hemolysis, Elevated Liver en-
zymes and Low Platelets). The prevalence of PE is 2-5% of first pregnancies, with about 
10% becoming complicated by the HELLP syndrome [2, 3]. PE and HELLP are a serious 
pregnancy complication as indicated by the associated high maternal and perinatal 
morbidity and mortality. In the developed world, 10–25% of all pregnancy-related 
maternal deaths are attributed to PE or HELLP [4]. About 1% of women with PE and 
HELLP deteriorate to eclampsia, a severe complication characterized by generalized 
convulsions most likely triggered by cerebral edema and vasospasm. After delivery, the 
typical clinical signs of PE and HELLP disappear in most cases within 48 hours. Perinatal 
mortality in PE is high (10%) and related to the central role of placental dysfunction in 
PE and the HELLP syndrome [5-7]. 
 Although placental dysfunction is generally considered to be the starting point in 
the clinical manifestation of PE and HELLP, its etiology is still obscure. Most nulliparous 
women who develop PE were normotensive before developing the hypertensive preg-
nancy disorder. Nevertheless, pre-pregnant obesity with or without metabolic syn-
drome or a family history of hypertension and PE are known to be predisposing condi-
tions [8-11]. Because of its enigmatic etiology, the only causal treatment of PE/HELLP is 
termination of pregnancy. 
 
Box 1: Definitions of hypertensive pregnancy complications used in this thesis 
Preeclampsia The de-novo development of hypertension (≥140/90 mmHg) in combination with the de-
novo development of proteinuria (≥300 mg urinary protein excretion/day) after 20 weeks 
pregnancy 
HELLP syndrome A combination of excessively high turnover rate of red blood cells (H: Hemolysis), rise in 
the circulating levels of liver enzymes secondary to liver cell necrosis (EL: Elevated Liver 
enzymes), and fall in number of circulating thrombocytes (LP: Low Platelet count, platelets 
< 100 x 109/l) developing in pregnancy. HELLP is considered a complication of PE or 
eclampsia, but may also develop without prior hypertension and/or proteinuria  
Eclampsia The development of generalized seizures in pregnancy, almost always in a woman 
previously diagnosed with pregnancy-induced hypertension, preeclampsia and/or the 
HELLP syndrome 
Early-onset  Onset of PE before the 34th week of pregnancy 
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Recurrent PE/HELLP, target for prediction and tailored management 
Although PE and HELLP are mostly considered disorders typically occurring in first 
pregnancies, pregnant women with a history of PE or HELLP are at increased risk of 
developing pregnancy-induced hypertension, PE, or the HELLP syndrome and/or fetal 
growth restriction due to placental insufficiency [13, 14]. Estimates of the recurrence 
rate vary from 0 to 31% for PE and from 3 to 7% for HELLP [15]. If PE or HELLP recurs in 
the second pregnancy, the clinical course of the recurrence tends to be more serious. 
This is indicated by a higher rate of early-onset PE. The latter is associated with a high-
er incidence of preterm pregnancy termination, and with it, more premature births, 
often accompanied by fetal growth restriction. It follows that these infants require 
more neonatal intensive care and suffer of more complications [16]. Therefore, current 
management of pregnant women with a history of early-onset PE entails close and 
frequent surveillance. Currently, there is no clinical practice guideline for the manage-
ment of these women. As a consequence, care varies per center, gynecologist and 
patient and –in the next pregnancy- depends on the perceived recurrence risk, the 
former patient’s anxiety and her demand for care. This opportunistic, informal type of 
care is referred to as care-as-usual (CAU). 
 Although a history of PE or HELLP is associated with an increased risk of recur-
rence, course and outcome of most next pregnancies will be normal. However, gyne-
cologists have neither a sensitive test to predict nor an effective management strategy 
in high-risk women to prevent or alleviate an early-onset recurrence. Therefore, identi-
fying the larger subgroup of women with a low risk of recurrence among former pa-
tients would restrict the burden of intensified surveillance to a relatively small sub-
group of former patients, thus lowering the level of medicalization and associated 
stress in most of former patients while also reducing (health care) costs. Recent trends 
support personalized medicine, which stands for the use of management tailored to an 
individual’s (risk) profile [17]. 
Predicting recurrent PE and HELLP 
Although earlier studies have identified several individual predictors for recurrent PE 
and HELLP, combining biomarkers for this purpose has only been explored recently 
[18-24]. Based on data collected from former patients, who not only experienced ear-
ly-onset PE or HELLP in their first pregnancy, but also had a well-documented course 
and outcome of their next pregnancy, we constructed a prediction model to estimate 
the recurrence risk in women with a history of PE/HELLP. We selected the following 
biomarkers in a multivariable logistic regression model: 1) Circulating fasting glucose 
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level measured at postpartum screening; 2) Gestational age at birth of the previous 
complicated pregnancy; 3) Birth of a small-for-gestational-age after that pregnancy; 4) 
Prepregnancy maternal body mass index, and 5) Chronic hypertension diagnosed prior 
to the second pregnancy [25]. The model was validated internally. Discrimination of 
the model, after correction for optimism by bootstrapping, was adequate (0.65; 95%CI: 
0.56-0.74). The calibration of the model was good, indicated by a non-significant Hos-
mer-Lemeshow test (p=0.11). 
The PreCare study 
The prediction model which was developed by our research group was expected to 
help in identifying women at really low risk of recurrent early-onset PE/HELLP. The 
PreCare study was designed to assess the effect of risk stratification using this predic-
tion model on maternal and neonatal outcome, patient satisfaction and (health care 
and societal) costs. 
 Based on the prediction model, women received either protocolized Medium Care 
(MC) or High Care (HC), depending on their predicted risk of developing early-onset 
recurrent PE/HELLP (recurrence risk guided care, RGC). The MC and HC protocols con-
tained 9-11 and 14-16 visits to the outpatient clinic, respectively. Women receiving HC 
could also be offered additional diagnostic tests. We compared RGC with CAU for both 
pregnancy-related health care and non-health care related costs (e.g. productivity loss, 
informal care) and generic health-related quality of life and adverse neonatal out-
comes. 
Economic evaluation in health care 
Nowadays, economic evaluations are becoming increasingly important as resources 
are finite. Therefore, new guidelines for clinical practice should also consider the im-
pact on health care expenses of evidence-based clinical management recommenda-
tions [26]. Economic evaluation in health care refers to the comparison of alternative 
treatment options in terms of their costs and consequences [27]. Alternative treat-
ment options refer to the range of ways in which health care resources can be used to 
increase population health, e.g. pharmaceutical and surgical interventions, screening 
and health promotion programs. Health care costs refer to the value of tangible re-
sources available to the health care system, e.g. buildings, equipment, consumables 
such as drugs and disposables, and clinical and other staff. Non-health care resources 
used in health care are e.g. time invested by a patient’s family. Consequences repre-
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sent all the effects of health care interventions other than those on resources. These 
generally focus on changes in an individual’s health, which can be positive or negative, 
but can also include other effects that individuals may value, such as reassurance and 
proper information provision. 
 There are several types of economic evaluations that differ by how the conse-
quences of health care interventions are taken into account [27]. A cost-minimization 
analysis only compares the costs of two interventions, presuming a similar beneficial 
health effect. A cost-benefit analysis considers both costs and effects in monetary 
terms. In a cost-effectiveness analysis, the cost-effectiveness ratio is used to compare 
two intervention options aimed at achieving the same goal. A special type of cost-
effectiveness analysis is called cost-utility analysis, in which the effect consists of 
health-related quality of life combined with life expectancy, so-called Quality Adjusted 
Life Years (QALYs). 
Patient satisfaction 
Most economic evaluations fail to adequately incorporate the patient’s perspective 
[28]. However, patient preferences are considered to be increasingly important in 
health care policy decision-making [28, 29]. One approach to consider the patient’s 
perspective in research is to investigate patient’s satisfaction with the treatment. The 
concept ‘satisfaction’ simply captures the patient’s point of view about the treatment 
received. Integrating the patient’s perspective in health care decision-making is im-
portant for several reasons. Exploring care quality from the patient’s perspective can 
reveal important information as a patient’s expectations from or satisfaction about a 
new treatment may differ from that of the clinical expert [30, 31]. The relevance of 
patient satisfaction is further emphasized by experimental evidence suggesting that 
user acceptability optimizes the cost-effectiveness of a new type of care (e.g. through 
protocol adherence), resulting in both better implementation and a higher quality of 
life in satisfied patients [32-34]. Patients may respond better to treatment and comply 
better to guidelines when they are satisfied with their care and treatment setting [35-
37]. Meanwhile, areas for improvement can be identified. 
 In the PreCare study as elaborated in this dissertation, we did our utmost best to 
explore whether patients were satisfied with RGC. Therefore, the evaluation of RGC 
not only consisted of a detailed assessment of (pregnancy) outcome and costs, but also 
of an evaluation of patient satisfaction. 
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Mental disorders in women with previous PE or HELLP 
Women with a history of PE/HELLP are at increased risk of developing posttraumatic 
stress disorder shortly after discharge from hospital, presumably as a direct conse-
quence of experiencing excessive stress because of giving preterm birth, emergency 
cesarean section, and maternal and neonatal complications [38]. A better understand-
ing of the incidence and severity of anxiety and depression in former PE or HELLP pa-
tients is expected to enable prevention and targeted interventions. Currently, diagno-
sis and management of anxiety and depression in the symptomatic phase of 
preeclampsia and the following postpartum period are still suboptimal [12]. 
Aim and outline of the thesis 
The main objective of this thesis was to compare RGC with CAU in the next pregnancy 
of women with a previous early-onset preeclamptic pregnancy, with respect to costs, 
pregnancy outcome, patient satisfaction, and the psychopathologic impact of 
PE/HELLP. The thesis consists of seven chapters. 
 Chapter 2 provides a detailed description of the study design. The PreCare study 
uses a before-after design, comparing costs and pregnancy outcome before (i.e. care-
as-usual, CAU) and after the introduction of the prediction model (i.e. recurrence risk 
guided care, RGC). Chapter 3 describes the care-as-usual part of the study, including 
hospital consumption, associated costs and pregnancy outcome. Characterizing CAU is 
an essential first step in identifying the positive and negative components of care, 
serving as a starting point for implementing evidence-based practice and identifying 
potential barriers. Chapter 4 describes the results of the economic evaluation. We 
calculated two incremental cost-effectiveness ratios (ICERs) consisting of 1) the cost 
per Quality Adjusted Life Year, i.e. QALY (mother unit of analysis, and 2) the cost per 
prevented adverse outcome child, i.e. NICU admission and/or death (child unit of anal-
ysis). Chapter 5 describes satisfaction rates in RGC subdivided into overall satisfaction, 
technical quality, interpersonal aspects, communication, time spent with doctor and 
access/availability/convenience. Based on Crow’s holistic model of satisfaction, we 
performed multivariate regression analyses to explore various contributors to satisfac-
tion and protocol adherence. Chapter 6 comprises a systematic review on whether or 
not a history of PE/HELLP is associated with anxiety and depression and whether 
PE/HELLP is an independent risk factor for developing anxiety and depression. In the 
final chapter, chapter 7, the results of this study are summarized and discussed. 
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Abstract 
Background 
Preeclampsia and HELLP syndrome may have serious consequences for both mother 
and fetus. Women who have suffered from preeclampsia or the HELLP syndrome, have 
an increased risk of developing preeclampsia in a subsequent pregnancy. However, 
most women will develop no or only minor complications. In this study, we intend to 
determine cost-effectiveness of recurrence risk guided care versus care as usual in 
pregnant women with a history of early-onset preeclampsia. 
Methods/design 
We developed a prediction model to estimate the individual risk of recurrence of early-
onset preeclampsia and the HELLP syndrome. In a before-after study, pregnant women 
with preeclampsia or HELLP syndrome in their previous pregnancy receiving care as 
usual (before introduction of the prediction model) will be compared with women 
receiving recurrence risk guided care (after introduction of the prediction model). 
 Eligible and pregnant women will be recruited at six university hospitals and seven 
large non-university tertiary referral hospitals in the Netherlands. 
The primary outcome measure is the recurrence of early-onset preeclampsia or HELLP 
syndrome in women allocated to the regular monitoring group. 
 For the economic evaluation, a modelling approach will be used. Costs and effects 
of recurrence risk guided care with those of care as usual will be compared by means 
of a decision model. Two incremental cost-effectiveness ratios will be calculated: 1) 
cost per Quality Adjusted Life Year (mother unit of analysis) and 2) cost per live born 
child (child unit of analysis). 
Discussion 
This is, to our knowledge, the first study that evaluates prospectively the efficacy of a 
multivariable prediction rule for recurrent hypertensive disease in pregnancy. Results 
of this study could either be integrated into the current guideline on Hypertensive 
Disorders in Pregnancy, or be used to develop a new guideline. 
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Background 
The disease 
Preeclampsia is defined as de novo development of hypertension (>140/90 mmHg) in 
combination with proteinuria after 20 weeks of gestation in pregnant women [1]. One 
of the most severe forms of this disease is called the HELLP syndrome, which is derived 
from the acronyms of the symptoms (Hemolysis, Elevated Liver enzymes and Low 
Platelets). 
 Preeclampsia (also termed early-onset preeclampsia) and HELLP syndrome may be 
life-threatening for both mother and child [2]. In the mother, these disorders predis-
pose to premature cardiovascular disorders such as chronic hypertension, ischemic 
heart disease and stroke later in life [3]. Studies in children, born after preeclamptic 
pregnancies and who were relatively small at birth, have shown an increased risk of 
stroke in adult life, an increased risk of coronary heart disease and metabolic syn-
drome [4-6]. Preeclampsia and especially HELLP syndrome are perceived by patients 
and their partners as a highly traumatic life event, both during and after pregnancy [7]. 
 In the United States and Europe, the prevalence of clinically relevant preeclampsia 
is approximately 2% of all pregnancies, with HELLP syndrome complicating preeclamp-
sia approximately in 10 to 20% of the cases [3, 8]. Maternal mortality rate in the Neth-
erlands due to hypertensive disease during pregnancy amounts to 4.0 per 100,000 live 
births in 1993-2002 [9]. 
 Although several risk factors have been identified, it is difficult to develop effec-
tive strategies for the prevention and treatment of these disorders [3]. Strategies ap-
plied nowadays are diverse and include antenatal surveillance, modification of life-
style, dietary interventions and pharmacological therapy. In the last two decades, clini-
cal guidelines for the management of preeclampsia and HELLP syndrome have been 
adopted in most developed countries [10-12]. 
 Clinical management of preeclampsia or HELLP syndrome depends on the gesta-
tional age at onset, severity of symptoms, laboratory abnormalities, size and condition 
of the unborn infant, disease progression and response to symptomatic treatment. 
 Mild preeclampsia is usually managed expectantly, as opposed to the manage-
ment of severe preeclampsia which is more pro-active consisting of the administration 
or magnesium sulphate, often combined with antihypertensives [13]. When gestation-
al age is less than 34 weeks and both maternal and fetal condition are satisfactory, it is 
usually recommended to prolong pregnancy for at least 48 hours to benefit optimally 
from the enhancing effect of corticosteroid administration on fetal lung maturation. 
Fetal surveillance is an important component of the management. Delivery is the only 
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causal treatment and therefore, the management of choice from 37 weeks’ gestation 
onward [14, 15]. 
The health care problem 
Although preeclampsia and HELLP syndrome are considered diseases of the first preg-
nancy, the risk of developing recurrent preeclampsia or HELLP syndrome is increased 
among parous women with preeclampsia and/or HELLP syndrome in their previous 
pregnancy. Sep et al. [16] conducted a literature search in order to identify prediction 
tests for recurrent disease. The recurrence rates reported vary from none to 31 per-
cent for preeclampsia and from 3 percent to 7 percent for HELLP syndrome. Fortunate-
ly, the majority of women with a history of preeclampsia or HELLP syndrome have 
uncomplicated subsequent pregnancies. 
 To the best of our knowledge there is at this moment no consensus about the 
management of pregnant women with a history of early-onset preeclampsia or HELLP 
syndrome. 
 As a result, follow-up and counselling of these patients varies per centre, gynae-
cologist and patient, and is largely based on the perceived risk by the responsible care 
provider of recurrence of the disease in the next pregnancy and the level of anxiety of 
the patient and its resulting demand for care. Formerly preeclamptic patients are often 
subjected to various medical screening programmes to detect associated disorders, 
followed by additional exams by other specialists or the initiation of some manage-
ment (postpartum evaluation). During a next pregnancy, care varies from regular sur-
veillance by the gynaecologist to intensive surveillance and counselling in order to 
identify the onset of adverse pregnancy course as early as possible. 
Motivation and relevance for the study 
This lack of uniformity in the treatment of these patients asks for more standardisa-
tion, e.g. by providing care tailored to the individualised risk assessment. 
 Current policy may not be efficient. Since only a small percentage of these women 
develop early-onset recurrent disease in their next pregnancy, clinical management in 
the next pregnancy may benefit from subdividing these women into subgroups with or 
without increased risk. The care provided to these women can then be adjusted to 
their actual risk profile. Particularly former patients at low risk are expected to benefit 
from this type of risk stratification. Recurrence risk guided care could lead to a sub-
stantial reduction of (health care) costs and an increased quality of care. 
 We have recently developed a multiple-factor model for the prediction of recur-
rent early-onset preeclampsia and/or HELLP syndrome during the current pregnancy in 
 21
women with a prior pregnancy complicated by preeclampsia and/or HELLP syndrome 
[17]. 
 The PreCare study (pregnant women with previous preeclampsia: efficiency of 
care based on recurrence risk estimation), was designed to (1) estimate cost-
effectiveness of recurrence risk guided care versus care as usual for pregnant women 
with a previous pregnancy being complicated by preeclampsia or HELLP syndrome and 
(2) to validate the prediction model externally on the basis of the results of a prospec-
tive cohort and to update the prediction model if necessary. To this end, we will use 
the prediction model to differentiate the intensity of monitoring of pregnant women 
with a history of early-onset preeclampsia and/or HELLP syndrome. Patients are as-
signed to either the ‘regular monitoring’ or ‘intensive monitoring’ protocol. We will 
compare this strategy, referred to as recurrence risk guided care, with usual care for 
these patients in The Netherlands. 
 
For this purpose, the following research questions were specified: 
1. What are the effects of recurrence risk guided care versus care as usual for preg-
nant women with a previous preeclamptic pregnancy, on maternal and fetal mor-
bidity and mortality? 
2. What are the effects of recurrence risk guided care versus care as usual on specific 
and generic quality of life, anxiety, depression and development of posttraumatic 
stress? 
3. What are the societal costs associated with the effects of recurrence risk guided 
care versus care as usual? 
4. What is the cost-effectiveness of recurrence risk guided care versus care as usual? 
Development of prediction model 
Although earlier studies have identified individual predictive factors for recurrent 
preeclampsia, a combination of variables for the prediction of recurrent preeclampsia 
have not been explored until recently. A simple prepregnant prediction rule which 
includes several predictive factors was developed by Sep et al. [18]. Unfortunately, 
patient data were collected from a single hospital and the number of included patients 
was limited (n=186). 
 We developed a prediction model to estimate the individual recurrence risk of 
recurrence of early-onset preeclampsia and/or the HELLP syndrome. We used data of 
407 women with early-onset preeclampsia and/or the HELLP syndrome in their first 
pregnancy, who had undergone subsequent postpartum screening and who had a 
recorded consecutive ongoing pregnancy for which maternal and neonatal outcomes 
were available. Data were collected from four university hospitals (Maastricht Univer-
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sity Medical Centre, University Medical Centre Utrecht, Academic Medical Centre Am-
sterdam and University Medical Centre St. Radboud Nijmegen), and one tertiary refer-
ral hospital (Máxima Medical Centre Veldhoven). 
 Predictors of recurrent disease were preselected based on availability in the five 
different hospitals, previous literature and gynaecologists’ expert opinion. Fasting 
circulating level of glucose measured at postpartum screening, gestational age at de-
livery of the first pregnancy, prior small-for-gestational-age newborn, chronic hyper-
tension and maternal BMI before the second pregnancy proved to be the predictors 
within a logistic regression model [17]. 
 Since a model tends to perform best in the derivation sample, called ‘overfitting’, 
we used bootstrapping techniques to internally validate the model. A shrinkage factor 
was computed to shrink the regression coefficients in order to get a more conservative 
risk estimate. 
Methods/design 
Design 
The PreCare study uses a before-after design, in which outcomes and costs before the 
introduction of the prediction model (i.e. care as usual) are compared with outcomes 
and costs after introduction of the prediction model (i.e. recurrence risk guided care). 
This study consists of two consecutive phases. In the first phase of the study, 50 wom-
en receiving care as usual will be followed prospectively from their first pregnancy-
related outpatient visit until 3 months post partum. These 50 women will receive ques-
tionnaires in order to measure quality of life, anxiety, depression, posttraumatic stress 
and costs outside the hospital. Retrospective data of an additional group of 200 wom-
en who have been treated with care as usual in the past will be collected later on. Then 
the prediction rule will be introduced. In the second phase, 250 women will receive 
either protocolised regular monitoring or protocolised intensive monitoring depending 
on their risk of developing early-onset preeclampsia or HELLP syndrome during their 
current pregnancy, as estimated on the basis of the prediction model. In regular moni-
toring, pregnant women are monitored less intensively than in intensive monitoring. 
Regular monitoring and intensive monitoring are described in detail in the ‘Monitoring 
protocols’ section. Figure 1 summarises the design. 
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Figure 1: Design of the study 
Participants/eligibility criteria 
In phase 1 and 2, pregnant women (aged 18 years and older) with preeclampsia and/or 
HELLP syndrome in their previous pregnancy who have visited the outpatient clinic 
until 16+6 weeks of pregnancy are eligible for participation in the PreCare study. 
 Given these general eligibility criteria, two subgroups are distinguished in recur-
rence risk guided care (phase 2). 
 In women who gave birth after early-onset preeclampsia or HELLP syndrome until 
33+6 weeks gestational age in the previous pregnancy, the prediction model is applied 
in order to allocate the participants to one of the two monitoring protocols. The data 
which are required as input parameters for the prediction model should be available. 
These variables mostly come from the postpartum evaluation. 
 Women who gave birth between 34 and 36+6 weeks gestational age in the previ-
ous pregnancy face a relatively small risk of developing recurrent preeclampsia or 
HELLP syndrome, compared to women who gave birth before 34 weeks. Therefore, 
they all are allocated to the regular monitoring subgroup [19]. 
 Women suffering from severe co-morbidity, such as diabetes mellitus, SLE, renal 
disease, cardiac disease or anti-phospholipids syndrome are excluded from the study 
as they will all receive (or have received where it concerns the retrospective patients) 
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intensive surveillance. The current study will not include women who gave birth after 
37 weeks gestational age. 
 The study population is recruited from six university hospitals and seven large 
non-university tertiary referral hospitals in the Netherlands: the Maastricht University 
Medical Centre, University Medical Centre St. Radboud Nijmegen, the Isala Clinics 
Zwolle, Erasmus Medical Centre Rotterdam, Academic Medical Centre Amsterdam, 
University Medical Centre Utrecht, Máxima Medical Centre Veldhoven, the University 
Medical Centre Groningen, Martini Hospital Groningen, Amphia Hospital Breda, Atrium 
Medical Centre Heerlen, Jeroen Bosch Hospital Den Bosch and Kennemer Hospital 
Haarlem. 
Recruitment procedures 
For the prospective assessment, 50 care as usual patients and 250 recurrence risk 
guided patients will be included in the study. 
 The research nurse or the gynaecologist of participating hospitals identifies eligi-
ble women by screening the appointment system of the outpatient clinic. After the 
pregnant woman has given informed consent for participation in the study, patients in 
phase 1 will be enrolled in care as usual whereas patients in phase 2 will be enrolled in 
recurrence risk guided care. 
 In recurrence risk guided care (phase 2), a simple web based risk calculator for the 
determination of recurrence risk and required intensity of surveillance has been devel-
oped and has been made accessible to gynaecologists and research nurses through the 
Internet. 
 Information about the recommended components of intensive monitoring and 
regular monitoring has been provided together with the risk calculator. 
 For the retrospective assessment, 200 patients who were treated according to 
care as usual will be used as a comparator group based on matching. Matching criteria 
will at least include maternal age (difference < 5 years) and gestational age at delivery. 
Consequently, at study completion, there will be 250 care as usual patients who will be 
compared with 250 recurrence risk guided patients. 
Data collection 
For the prospective assessment (n=50 care as usual; n=250 recurrence risk guided 
care), baseline demographics, past obstetric and medical history will be recorded in 
case report forms. Information is obtained on the condition of mother and child, infant 
weight, infant length, morbidity and mortality from the infant and maternal records. If 
applicable, details of the admittance of the child to the neonatal intensive care, high 
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care or medium care unit will also be collected. All activities in the hospital will be 
documented until three months postpartum. 
 We will assess not only clinical outcomes, but also health-related quality of life by 
using the EQ-5D [20], anxiety by using the STAI [21], depression by using the Beck De-
pression Inventory [22] and posttraumatic stress by using the PTSD Symptom Scale 
[23]. The QoL questionnaires will be administered at 3-month intervals between base-
line (before 20 weeks of pregnancy), at 29 weeks of pregnancy, ten days and three 
months postpartum. Costs outside the hospital, such as GP care, midwife and materni-
ty care, productivity losses and out-of-pocket expenses will be obtained by means of a 
retrospective cost questionnaire with a recall period of 3 months. Long-term follow up 
of the women and children may be possible, but is not included in the current study. 
 For women enrolled in the retrospective assessment (n=200), all data described 
above will be collected, except data on health-related quality of life, anxiety, depres-
sion, posttraumatic stress and costs outside the hospital. 
Monitoring protocols 
Development of the protocols 
All gynaecologists of the participating centres were approached and they participated 
in a consensus process, during which the final protocols were designed. Nearly all were 
obstetricians specialised in hypertensive disorders of pregnancy. After reaching con-
sensus, the protocols were distributed among all providers of care in the study. 
The protocols 
Figure 2 shows the process of recurrence risk guided care. 
Regular monitoring 
Women will visit the outpatient clinic 9 - 11 times: (8, 12), 16, 20, 24, 28, 32, 36, 38, 39 
and 40 weeks gestational age. The visits at 16 and 20 weeks will be scheduled after the 
first trimester screening procedure and the routine ultrasound screening for structural 
malformations, respectively. If feasible, six of these eleven visits (12, 20, 28, 36, 39, 40) 
ought to be performed by the same obstetrician, whereas the remaining five (reassur-
ing) visits (8, 16, 24, 32, 38) may be performed by a nurse-practitioner or may be per-
formed by the gynaecologist of the referring clinic (as of 32 weeks, in regular and in-
tensive monitoring). 
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Figure 2: Recurrence risk guided care (phase 2) 
 
Intensive monitoring 
Women will visit the outpatient clinic 14 – 16 times: (8, 12), 16, 18, 20, 22, 24, 26, 28, 
30, 32, 34, 36, 38, 39 and 40 weeks gestational age. 
 
At two occasions during an intensive monitoring pregnancy (16 and 20 weeks), the 
patient will undergo a series of diagnostic tests, which consist of: 
1. Measurements in urine: (micro)albuminuria, creatinine, protein (protein serves to 
calculate the protein-to-creatinine ratio) 
2. Measurements in blood: Haemoglobin, platelet count, mean platelet volume, 
creatinine, urate, CRP, glucose, fibronectin, Flt-1, endoglin 
3. 24 h blood pressure monitoring. This assessment is optional (not obligatory) 
4. Assessment of the Doppler flow velocity profile in both uterine arteries (at 20 
weeks) 
 
Activities other than, or additional to those described in the regular monitoring and 
intensive monitoring protocols (such as intercurrent admissions, additional outpatient 
visits or diagnostic testing, or telephone/e-mail contacts) will be registered. 
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Study outcomes 
Recurrence risk guided care will be compared with care as usual with respect to sever-
al outcomes. 
 Primary outcome is the occurrence of either early-onset preeclampsia or HELLP 
syndrome. Early-onset preeclampsia and early-onset HELLP syndrome are defined 
according to the criteria of the International Society for the Study of Hypertension in 
Pregnancy with the criterion of delivery before 34 weeks after the last menstrual peri-
od [24]. Secondary clinical outcome measures are: gestational age of onset of 
preeclampsia, eclampsia, HELLP syndrome, intrauterine growth restriction, caesarean 
section, admission to the neonatal intensive care unit (NICU), gestational age at deliv-
ery and maternal/infant mortality. Other secondary outcome measures are societal 
costs, quality of life, anxiety, depression, development of posttraumatic stress, satis-
faction with treatment, protocol adherence and cost-effectiveness. 
Statistical analysis 
Sample size 
Sample size calculation was based on the expected fraction of women assigned to 
regular monitoring either on the basis of the prediction rule or gestational age at the 
time of previous delivery (67%), the expected failure rate within this category (2%), a 
type I error (one-sided) of 0.05 and a type II error of 0.2. In order to be able to exclude 
failure rates of 5% or more, 150 patients assigned to regular monitoring are needed. 
This means that results of about 225 patients in the recurrence risk based care are 
needed. The estimated number of 250 allows for drop out and incomplete data of 25 
patients. 
Data analysis 
The primary analysis concerns the incidence of recurrent early-onset preeclampsia or 
HELLP syndrome in both groups (recurrence risk guided care versus care as usual). 
Analyses will be adjusted for potential confounders (including demographic factors). 
Confidence intervals will be adjusted by means of multilevel analysis (hospital). 
 We will also analyse whether the new patient data indicate the need for an up-
date of the predictive model. For this purpose, we will first compare the characteristics 
of the original population used for model development with the new population, the 
so-called “validation population”. For example, the incidence of early-onset 
preeclampsia may differ between the original and validation population. It is also pos-
sible that the latter population has a different case-mix (i.e. differences in distributions 
of the predictors in the population), because, e.g., more hospitals are included. In 
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addition, different predictor-outcome associations and additional predictors, that are 
not included in the model but are either more or less frequent in the new population, 
could play a role. We will also assess model performance in the validation population 
by comparing sensitivity, specificity, positive and negative predictive values and dis-
crimination and calibration compared to the performance in the derivation population. 
 If the analysis should indicate lower accuracy than expected, we will analyse to 
what extent all these factors indeed affect the model’s accuracy and update the model 
to obtain adequate accuracy. Updating of the model will be done by means of re-
calibration (step 1) and model revision (step 2) [25-27]. 
Economic evaluation 
A cost-effectiveness analysis will be performed from a societal perspective, comparing 
the costs and effects of recurrence risk guided care versus care as usual. The time 
horizon of the study is 9 months (3 months amenorrhea - 3 months post partum). 
Discounting is not relevant given the short time horizon. 
 The cost analysis will be performed according to the Dutch guidelines for cost 
calculations [28]. All hospital resource use and costs associated with care for pregnant 
women and their newborns will be calculated from study entry until 3 months post 
partum and include costs such as outpatient visits and hospital admissions. Cost prices 
will be obtained from participating hospitals. If prices are not readily available, di-
rective prices will be used [28] or additional calculations will be made. Costs in the 
analysis also include direct non-health care costs (travel costs) and indirect costs 
(productivity loss). 
 Effect parameters are clinical outcomes, health related quality of life, anxiety, 
depression and posttraumatic stress. 
 Currently, no economic evaluation methods are available that integrate health 
outcomes of both mother and child into a single outcome measure. However, 
preeclampsia may have health effects for both the pregnant women and her (unborn) 
child. Therefore, the main cost-effectiveness analysis will involve calculating two in-
cremental cost-effectiveness ratios (ICERs) expressing 1) the cost per Quality Adjusted 
Life Year (QALY, mother unit of analysis) and 2) the cost per live born infant (child unit 
of analysis). To this end, a decision model will be developed. Modelling in economic 
evaluation is considered useful for example when experimental observations from a 
trial are missing, which in this study applies to some parameters in the care as usual 
group [29, 30]. 
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Ethical considerations 
This study has been approved by the ethical committee of the University Hospital 
Maastricht (Ref.no. MEC 07-2-078). A total of six academic and seven non-academic 
hospitals participate in the study; all of them have completed their obligatory feasibil-
ity assessment procedure successfully. Informed consent is being obtained from all 
patients prior to enrolment into the study. 
Discussion 
This study is expected to yield information on health outcomes and costs of adjusting 
the level of care to the estimated probability of recurrent preeclampsia. The results 
can provide a basis for more uniform (and evidence-based) guidelines for care for 
formerly preeclamptic women and possibly lead to more cost-effective provision of 
health care. With respect to health care costs, it is expected that mean costs per pa-
tient will decrease as a result of a reduction in intensive maternal and fetal surveil-
lance. Potential savings can be even higher, since the majority of women assigned to 
regular monitoring may be adequately served by care provided by in-hospital midwifes 
[31]. 
 The close cooperation with many centres enables us to reach a representative 
study population of pregnant women who have experienced preeclampsia in their 
previous pregnancy, which enhances the applicability of the results to all former 
preeclamptic women. Results of this study will be disseminated by means of presenta-
tions at scientific meetings and peer-reviewed publications. Study outcomes will also 
be communicated directly to the NVOG (Dutch Association of Obstetrics and Gynae-
cology), KNOV (Royal Dutch Association of Midwives), and the Dutch HELLP syndrome 
foundation. In addition, we will cooperate with the NVOG in order to produce recom-
mendations for the formulation of guidelines. The recommendations could either be 
integrated into the current guideline on Hypertensive Disorders in Pregnancy, or be 
used to develop a new guideline. The results of this study will be used to standardise 
the postpartum evaluation of women with a recent history of preeclampsia or HELLP 
syndrome. It is expected that the number of tests in the postpartum evaluation will 
not only be reduced, but also synchronised. 
 A randomised controlled trial design is usually preferred over any other design. 
However, for this study such a design was not considered applicable. A before-after 
study was chosen (instead of a fully prospective, randomised study) because of the risk 
of care as usual being contaminated with the regular monitoring and intensive moni-
toring protocols. Because current care as usual is not standardised, and blinding of the 
participating gynaecologists with respect to predictive factors for recurrent disease is 
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practically unfeasible, a randomised design could reduce the contrast between study 
arms and thereby threaten the validity of the results. 
 As the care provided to women assigned to regular monitoring is less intense, a 
possible consequence may be that the detection of clinical signs of preeclampsia or 
HELLP syndrome is somewhat later than in the current care as usual approach. Howev-
er, we do not expect this to lead to adverse maternal or fetal outcomes, because the 
prediction model suggests that the recurrence rate in this group is low (< 1%) whereas 
there is also increased alertness for early signs of pregnancy complications in women 
with a history of preeclampsia or HELLP syndrome. 
 In summary, the PreCare study is designed to provide information on whether 
recurrence risk guided care is a worthwhile strategy compared to current care for 
pregnant women who suffered from preeclampsia or HELLP syndrome during their 
previous pregnancy. 
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Abstract 
Objective 
To explore hospital costs by pregnant women with a history of early-onset preeclamp-
sia or HELLP syndrome, managed according to customary, but non-standardized prena-
tal care, by relating maternal and child outcome to maternal health care expenditure. 
Study design 
This was a cohort study, in women of 18 years or older who suffered from early-onset 
preeclampsia or HELLP syndrome in their previous pregnancy (n=104). We retrieved 
data retrospectively from hospital information systems and medical records of patients 
who had received customary, non-standardized prenatal care between 1996 and 2012. 
Our analyses focused on the costs generated between the first antenatal visit at the 
outpatient clinic and postpartum hospital discharge. Outcome measures were hospital 
resource use, costs, maternal and child outcome (recurrence of preeclampsia or HELLP 
syndrome, incidence of eclampsia, gestational age at delivery, intrauterine fetal de-
mise, small-for-gestational-age birth and low 5 minutes’ Apgar score). We used linear 
regression analyses to evaluate whether maternal and child outcome and baseline 
characteristics correlated with hospital costs. 
Results 
Maternal hospital costs per patient averaged € 8,047. Main cost drivers were maternal 
admissions and outpatient visits, together accounting for 80% of total costs. Primary 
cost drivers were preterm birth and recurrent preeclampsia or HELLP syndrome. 
Conclusion 
Hospital costs in the next pregnancy of formerly preeclamptic women varied widely 
with over 70% being medically unexplainable. The results of this study support the 
view that care standardization in these women can be expected to improve costs and 
efficacy of care without compromising outcome. 
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Introduction 
Preeclampsia (PE) affects about 2-5% and the syndrome of Hemolysis, Elevated Liver 
enzymes and Low Platelets (HELLP) 0.5% of all pregnancies (1, 2). Women with a histo-
ry of PE or HELLP are at increased risk of recurrence in their next pregnancy (1, 2). 
Women who experienced early-onset PE in the first pregnancy have a 6.6-fold higher 
risk of recurrence in their next pregnancy than women who completed a normotensive 
first pregnancy (3). Therefore, gynecologists often provide extensive follow-up and 
counseling to these women, both postpartum and during their next pregnancy. How-
ever, only 7% of these former patients will actually develop a recurrent early-onset PE 
in their next pregnancy (2). Therefore, current clinical management may be excessive 
in most former patients (4-6). Nowadays, the challenge of rapidly rising health care 
costs asks for close scrutiny on costs and benefits of all medical treatments. At this 
moment, there are no evidence-based and standardized clinical practice guidelines for 
the management of pregnant women with a history of early-onset PE or HELLP. As a 
consequence, the intensity of follow-up can be expected to vary per center, gynecol-
ogist and patient, influenced by subjective factors, such as the perceived recurrence 
risk in the next pregnancy and the patient’s neuroticism, anxiousness and associated 
demand for care (7, 8). This practice variation is referred to as care-as-usual (CAU): 
“the full spectrum of patient care practices in which clinicians have the opportunity to 
individualize care” (9). Describing CAU is an essential first step in understanding and 
identifying potential options to ameliorate the costs and efficiency of care. 
 This study aims to describe the hospital costs of CAU in a cohort of pregnant 
women with a previous pregnancy complicated by early-onset PE/HELLP in the Nether-
lands, and whether these costs relate to pregnancy outcome. 
Material and methods 
Study design 
This study is part of a multicenter “before-after” study (the PreCare study) designed to 
compare effects and costs of recurrence risk guided care (RGC) with those of CAU (10). 
In RGC (the ‘after’ part of the study), pregnant women were assigned to either Medi-
um or High Care, depending on their anticipated risk to develop recurrent PE/HELLP, 
estimated at booking using a prediction model (11). In CAU (the ‘before’ part of the 
study) gynecologists were asked to treat their patients as they deemed appropriate. All 
women in our study received low-dose aspirin from 12 to 37 weeks pregnancy, a prac-
tice which became universally accepted in the Netherlands shortly after the CLASP 
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study (1994). The CLASP study provided evidence for a low-dose aspirin –taken from 
early pregnancy onwards- to lower the risk of developing PE in women at increased 
risk of developing PE (12). This practice has not changed since. For this study we used 
data retrieved from hospital information systems and medical records of patients who 
had received CAU between 1996 and 2012 in six university and three non-university 
hospitals in the Netherlands: Maastricht University Medical Center, Erasmus Medical 
Center Rotterdam, Academic Medical Center Amsterdam, Radboud University Medical 
Center Nijmegen, University Medical Center Groningen, University Medical Center 
Utrecht, Atrium Hospital Heerlen, Onze Lieve Vrouwe Hospital Amsterdam, Amphia 
Hospital Breda. 
Participants 
Pregnant women of over 18 years of age, with their previous pregnancy being compli-
cated by PE and/or the HELLP syndrome, requiring pregnancy termination before 37 
weeks, were eligible for enrolment. We excluded women with severe co-morbidity 
(diabetes mellitus, systemic lupus erythematosus, renal disease and cardiac disease or 
the anti-phospholipid syndrome). 
Estimation of hospital resource use 
Hospital resource use was assessed by retrieving data from hospital information sys-
tems and medical records. All cost-generating activities in the hospital (maternal ad-
missions, outpatient visits, maternal lab tests, mode of delivery, etc.) were registered 
at the patient level and recorded online in case report forms (CRFs). We classified in-
tensive care and obstetrical ward admissions separately and categorized childbirth 
depending on whether or not the delivery was induced and whether or not delivery 
required termination by forceps/vacuum extraction or cesarean section. Variation in 
resource use was then determined and evaluated in relation to baseline characteristics 
and maternal and child outcome. 
Estimation of unit costs 
We performed cost calculations using the Dutch manual for cost research in health 
care, a methodological reference for costing studies in the Netherlands (13). The cost 
analysis was performed from the hospital perspective and covered the interval from 
conception until maternal postpartum discharge from hospital. Unit prices are pre-
sented in 2011 Euros. If necessary, costs were adjusted to the 2011 price level using 
the consumer price index (14). In order to assess whether a time effect was present in 
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the data, we tested the calendar year from which the data were retrieved (1996-2012) 
for its association with maternal hospital costs. For each individual patient, we calcu-
lated a ‘time trend variable’ by subtracting year of delivery from 1996. 
Pregnancy outcome 
Baseline characteristics of participants, such as obstetric and medical histories, and 
maternal and child outcome were recorded in CRFs. We considered the following types 
of adverse maternal outcome to be relevant for analysis: recurrent PE/HELLP, requiring 
pregnancy termination before the 34th week, preterm birth (delivery < 37 weeks) and 
recurrence of PE/HELLP/eclampsia, irrespective of gestational age. Meanwhile, intrau-
terine fetal demise (IUFD), low birth weight (birth weight centile < 10%) and 5-min. 
Apgar score (below 7) were considered adverse child outcome. 
Details of ethical approval 
This study was approved by the medical-ethical committee of the University Hospital 
Maastricht (Ref.no. MEC 07-2-078). All hospitals successfully completed their obligato-
ry feasibility assessment procedure. 
Statistical analysis 
Prior to analysis, we checked completeness and validity of our dataset. Two of the 
authors (DD and SvK) contacted the research nurses in the participating hospitals to 
maximize the effort to retrieve missing data or to correct identified inconsistencies in 
the data. If missing values could not be retrieved, we performed regression imputation 
(except for baseline characteristics, Table 1). If the total number of CRF-registered 
outpatient visits was unrealistically low (below 5), the number was considered missing, 
and also imputed by single imputation (15). 
 We used simple statistics, such as frequencies, percentages, means and standard 
deviations (SDs) to describe population characteristics at baseline, resource use (use of 
hospital care), hospital costs, inter-hospital variation and maternal and child outcome. 
First, in order to get insight into the crude associations between maternal and child 
outcome on the one hand and maternal hospital costs on the other hand, all variables 
were examined by univariate regression analyses for their relation with maternal hos-
pital costs. In the second step, all these variables were included in a multivariate linear 
regression model using a backward selection procedure (α=0.10) with total maternal 
hospital costs as dependent variable. In a first additional analysis, we applied the same 
linear regression model (using a backward selection procedure, α=0.10), including only 
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the subgroup of patients who had not developed recurrent PE/HELLP (n=76), to enable 
identification of other factors also contributing to maternal hospital costs, in the ab-
sence of recurrent PE/HELLP. This separate analysis was expected to increase the dis-
criminatory power of our study as PE/HELLP recurrence requiring hospital admission 
tended to dominate total hospital costs. Collinearity between the variables in the 
model was assessed by examining the tolerance and variance inflation factor for each 
independent variable. We verified normality of the residuals using a normal probability 
plot of the residuals. 
 For all the analyses, we used the Statistical Package for the Social Sciences 20.0 
(SPSS Inc., Chicago, USA) and Microsoft Excel 2010 (Microsoft Corp., Redmond, CA). 
Results 
Study population 
A total of 104 patients fulfilled the eligibility criteria. Table 1 lists the baseline charac-
teristics of the study population. For 64 women (61.5%) we were unable to retrieve 
from the records whether or not they had preexisting hypertension. In addition, in 
two-third of the participants (n=70), we were unable to retrieve the birth weight data 
of the infants born after the complicated pregnancy. Therefore, we missed in > 50% of 
the participants (n=59) information on whether or not they had given birth to an SGA 
infant in that pregnancy. 
Hospital resource use and associated costs 
Table 2 lists data on prenatal care, childbirth, and hospital admission. The mean length 
of hospital stay for those requiring hospitalization was 8 days (SD=6.72). About half of 
the women (51%) required cesarean birth, whereas ≈30% delivered spontaneously. 
 Patients visited the outpatient clinic on average 17 times. Total costs averaged 
€8,047 with major contributors being maternal admissions (57%) and outpatient visits 
(26%). 
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Table 1: Characteristics of the study population 
Maternal characteristics at conception of the target pregnancy  
Maternal age at conception, years (SD) 30.7 (5.0) 
Body mass index, kg/m2 (SD) 27.3 (6.1) 
Primiparous, n (%)  93 (89.4) 
Multiparous, n (%) 11 (10.6) 
  
Characteristics of previous pregnancy  
Gestational age at delivery (weeks) 31.1 (3.8) 
  < 34 weeks, n (%)  78 (75) 
  34 to 36+6 weeks, n (%)  26 (25) 
PE, n (%) 95 (91.3) 
HELLP syndrome, n (%) 59 (56.7) 
Eclampsia, n (%) 5 (4.8) 
IUFD, n (%) 14 (13.5) 
Birth weight, g (SD) 1408 (765) 
Data are given as mean ± SD or as percentages 
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Table 2: Mean costs, resource use, subtotal and total costs in Euros for care-as-usual (CAU)  
All patients Cost per unit,  
€ (2011)a 
Volumes of 
use for CAU 
Costs for CAU per patient,  
means (€) (n=104) 
   Costsb % of total 
Direct health care costs mother 
 Tests and procedures, bloodc Various/Procedure1 n.a. 92.59 (106.59) 1.15% 
 Tests and procedures, urinec Various/Procedure1 n.a. 40.83 (59.13) 0.51% 
 Outpatient clinic gynecologist 66.32 – 133.68 / Visit2 16.85 (7.46) 2,066.11 (1,048.95) 25.68% 
 Fetal ultrasound 35.99/Determination1 6.39 (5.30) 229.90 (190.55) 2.85% 
 Automated blood pressure 
monitoring 
1.52/Determination1 9.73 (15.79) 14.79 (24.00) 0.18% 
Maternal admission peripartum 
period 
450.79 – 595.87 – 
2,262.24/day2 
8.01 (6.72) 4,616.45 (3,995.88) 57.37% 
 Mode of delivery 
  Spontaneous 
  Spontaneous after induction 
  Instrumental 
  Instrumental after induction 
 Cesarean section 
 Cesarean section after  
  induction 
 Cesarean section after  
  vacuum/forceps 
 Subtotal mode of delivery 
 
766.27/Procedure1 
781.21/Procedure1 
786.81/Procedure1 
801.81/Procedure1 
1134.60/Procedure1 
1149.60/Procedure1 
 
1921.41/Procedure1 
 
0.298 
0.029 
0.048 
0.038 
0.51 
0.077 
 
0 
 
228.5 
22.66 
37.77 
30.47 
578.65 
88.52 
 
 
 
986.25 (180.10) 
 
 
 
 
 
 
 
 
 
 
12.26% 
 Total costs mother   8,046.92 (4,048.63) 100% 
Data are given as mean ± SD 
a) Source of unit price; 1) Dutch manual (Oostenbrink et al., 2004); 2) Dutch manual (Hakkaart-van Roijen et 
al., 2010); b) Total costs may not exactly be the product of cost per unit and volumes of use due to rounding; 
c) As tests and procedures varied in type and costs, n.a. (not applicable) is shown for the volumes of use. 
Practice variation 
The number of outpatient visits between centers varied widely, though, without a 
consistent pattern (ANOVA, p=0.662). Although the mean number of visits to the out-
patient clinic in the 9 participating hospitals ranged from 13 to 20 (Table 3), individual 
cases varied as much as from 5 to 37 visits. 
 
  
 41
Table 3: Practice variation between centers with regard to outpatient visits 
Center N Minimum Maximum Mean (SD) 
A 18  5 37 18 (11.6) 
B 11  8 37 18 (8.3) 
C 13  7 26 13 (4.9) 
D  7 12 23 16 (3.7) 
E  3  6 28 19 (11.9) 
F 20  9 28 17 (4.6) 
G  7  6 20 15 (4.9) 
H  9 12 37 19 (7. 5) 
I 16  8 37 15 (7.3) 
University  87  5 37 16 (7.8) 
Non-university 17  6 28 16 (5.8) 
Pregnancy outcome of mother and child 
Table 4 lists maternal and child outcome variables. All pregnancies were singleton, 
resulting in the birth of 51 boys and 53 girls, including 5 perinatal deaths. 
 
Table 4: Maternal and child outcome of the target pregnancy 
Maternal outcome    
Gestational age at delivery, weeks (SD) 37.1 (4.3) 
  < 34 weeks, n (%)  18 (17.3) 
  34 to 36+6 weeks, n (%)  9 (8.7) 
  after 37 weeks, n (%)  77 (74.0) 
Recurrent early-onset PE, n (%) 7 (6.7) 
Recurrent PE (all cases), n (%) 16 (15.4) 
Recurrent early-onset HELLP, n (%) 4 (3.8) 
Recurrent HELLP (all cases), n (%) 5 (4.8) 
Eclampsia, n (%) 2 (1.9) 
 
Child outcome    
IUFD, n (%) 5 (4.8) 
Birth weight, g (SD) 2,833 (1,094) 
SGA, n (%) 26 (25) 
Five minutes’ Apgar score (SD)  9 (1.2) 
Data are given as mean ± SD or as percentages 
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Relation between mother and child characteristics and maternal costs 
We examined how maternal hospital costs related to maternal and child characteris-
tics. We made a distinction between pre-existing baseline characteristics (including 
features of the index pregnancy), and outcome of the target pregnancy (until postpar-
tum discharge). In univariate regression analyses, maternal hospital costs in older 
women were higher for each variable (p=0.036). The costs increased with increasing 
parity and gravidity (p=0.014 and p=0.010, respectively). Hospital costs for patients 
who developed recurrent PE/HELLP were markedly higher than those for their coun-
terparts not developing a recurrence (€3,720; p=0.000). We also observed an inverse 
relation of hospital costs with gestational age at birth and birth weight (Table 5). 
 
Table 5: Univariate regression analyses examining the relation between mother and child characteristics and 
maternal hospital costs, including all women (n=104) 
Variable n B (SE)  p R2 
Maternal characteristics 
Baseline (before and index pregnancy) 
Age at conception (years) 104 165 (78)  0.036* 0.043 
Gravidity 104 1111 (443)  0.014* 0.058 
Parity 104 2157 (820)  0.010* 0.064 
BMI 104 -96 (78)  0.221 0.015 
Gestational age delivery index pregnancy (weeks) 104 -1 (107)  0.990 0.000 
Time trend (years) 104 154 (107)  0.156 0.010 
Outcome (target pregnancy) 
Recurrence of PE/HELLP (0=no; 1=yes) 92 3720 (967)  0.000* 0.141 
Gestational age at delivery (weeks) 104 -290 (88)  0.002* 0.094 
Child characteristics 
Baseline (index pregnancy) 
SGA (0=no; 1=yes) 104 -1195 (799)  0.138 0.021 
Outcome (target pregnancy) 
Birth weight (g) 104 -1 (0)  0.003* 0.086 
IUFD (0=no; 1=yes) 103 -1952 (1776)  0.274 0.012 
*Significant results (α was set at 0.10) 
Beta coefficients and their SEs are rounded 
 
In a backward multivariate regression analysis, after adjustment for all other factors, 
only the development of recurrent PE/HELLP (B=3332; p<0.0001), the gestational age 
at delivery of the target pregnancy (B=-240; p=0.010) and the occurrence of IUFD (B=-
4803; p=0.005) were independent predictors of maternal hospital costs. Together, 
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these variables explained 26% of the hospital costs (R2). Only outcome variables are 
associated with maternal hospital costs. 
 We repeated these univariate and multivariate regression analyses in the sub-
group of women who did not develop recurrent PE/HELLP (n=76 out of 104). Gesta-
tional age at delivery (target pregnancy) and birth weight did no longer contribute to 
the relation in the univariate analyses (Table 6). 
 In the backward multivariate analysis in this subgroup, only maternal BMI was an 
independent predictor of maternal hospital costs (B=-133; p=0.059). About 4.8% of the 
costs (R2) were explained by BMI. 
 
Table 6: Univariate regression analyses examining the relation between mother and child characteristics and 
maternal hospital costs, including only women without a recurrence PE/HELLP (n=76)  
Variable n B (SE)  p R2 
Maternal characteristics 
Baseline (before and index pregnancy) 
Age at conception (years) 76 189 (74)  0.012* 0.082 
Gravidity 76 905 (423)  0.036* 0.058 
Parity 76 2421 (736)  0.002* 0.128 
BMI 76 -128 (78)  0.105 0.035 
Gestational age delivery index pregnancy (weeks) 76 -29 (108)  0.790 0.001 
Time trend (years) 76 119 (101)  0.240 0.005 
Outcome (target pregnancy) 
Gestational age at delivery (weeks) 76 -112 (101)  0.273 0.016 
Child characteristics 
Baseline (index pregnancy) 
SGA (0=no; 1=yes) 76 -119 (800)  0.882 0.000 
Outcome (target pregnancy) 
Birth weight (g) 76 -0 (0)  0.502 0.006 
IUFD (0=no; 1=yes) 75 -826 (1808)  0.649 0.003 
*Significant results (α was set at 0.10) 
Beta coefficients and their SEs are rounded 
Comments 
This study explored the hospital cost drivers in relation to maternal and child outcome 
of 104 next pregnancies in women with a history of early-onset PE/HELLP, managed 
according to CAU. Maternal costs per patient averaged €8,047. As expected, the most 
important contributors to hospital costs were maternal admissions and outpatient 
visits, which together comprised over 80% of the total maternal costs. Costs associated 
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with hospital neonatal care were excluded as they are not part of the care provided by 
gynecologists/obstetricians. We did not find similar studies on costs of ‘uneventful’ 
pregnancies or guidelines about how to standardize the care in next pregnancies in 
women with a history of early-onset PE/HELLP. 
 This study focuses on the wide variation in CAU for pregnant women with a histo-
ry of PE or HELLP, caused among others, by the wide range (5 to 37) of number of 
outpatient visits. The variation in maternal hospital costs was not explained by the 
calendar year of pregnancy (period 1996-2002). Maternal hospital costs in these wom-
en were particularly high when recurrent PE/HELLP had developed or when pregnancy 
led to preterm birth. Although multiple regression analyses indicated that these com-
plications in the target pregnancy had an important impact on maternal hospital costs, 
over 70% of the variation in maternal hospital costs could not be accounted for by all 
factors included in our regression models, i.e. baseline characteristics of the partici-
pants and maternal and child outcome. An additional multiple regression analysis, 
including only the larger subgroup of women who did not develop recurrent PE/HELLP, 
showed that only BMI was an independent predictor of maternal hospital costs. In fact, 
all outcome variables that contributed to maternal hospital costs in the previous multi-
variate regression analysis were related to PE/HELLP recurrence. It is conceivable that 
other mostly subjective factors contributed to the costs (such as patient preferences 
and doctor’s practice style) (16). These factors are not necessary superfluous as they 
may have improved patient’s satisfaction, a yield not quantifiable in our study. These 
inferences indicate that clinical and outpatient care provided to this specific cohort of 
pregnant women and with it, the cost-effectiveness, can be improved by standardiza-
tion of care (17, 18). Therefore, we propose a standardized management protocol 
based on recurrence risk stratification. This method is one of the possibilities, which 
can be expected to reduce the number of superfluous outpatient visits and diagnostic 
procedures. 
Strengths and limitations 
This is the first study reporting on the variability in patterns of care (and associated 
costs) provided to pregnant women with a history of early-onset PE/HELLP in the 
Netherlands, a form of care hampered by the lack of a standardized management 
protocol. 
 The results of this study indicate that the care for this population is not cost-
effective. One important quality aspect of this study was our standardized procedures 
to retrieve data from medical records. The data were collected within the well-
organized structure of the Dutch Obstetric Consortium (19). Obviously, our study has 
also a number of limitations. First, inherent to its retrospective nature, some variables 
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may have been underestimated because of their incomplete registration in the medi-
cal records (information bias). Only few sociodemographic data were registered. Pre-
vious studies showed that for example educational level, ethnicity and income are 
factors that affect health care consumption (20, 21). Such sociodemographic infor-
mation can help in the development of optimal intervention strategies and appropriate 
health policies. Another aspect is that most of the data in this study were obtained in 
university hospitals. However, in the Netherlands, most women with a history of early-
onset PE/HELLP will get their prenatal care in the next pregnancy in university hospi-
tals. It should be noted that differences in the risk level of the recruited local patient 
populations, in the absence of a generally accepted guideline, can be expected to in-
fluence intensity and content of the care offered in each participating hospital and 
with it, reduce the inter-hospital comparability. We consider this study a first step 
towards the development of cost-effective management in the next pregnancy of 
women, who experienced early-onset PE/HELLP in their previous pregnancy. 
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Abstract 
Objective 
To compare the cost-effectiveness of recurrence risk guided care with care-as-usual in 
the next pregnancy provided to women whose preceding pregnancy was complicated 
by early-onset preeclampsia or the HELLP syndrome. 
Study design 
We conducted a before-after study in six university and six non-university hospitals in 
the Netherlands. A total of 311 newly pregnant, former patients were included. We 
implemented a model to predict recurrent early-onset preeclampsia or HELLP and 
compared recurrence risk guided care with care-as-usual with respect to costs, effec-
tiveness and cost-effectiveness. Two incremental cost-effectiveness ratios (ICERs) were 
calculated expressing 1) the hospital perspective reflected in cost per prevented ad-
verse neonatal outcome, and 2) the societal perspective reflected in cost per Quality 
Adjusted Life Years (QALY).  
Results  
From the hospital perspective, recurrence risk guided care was less costly (costs 
€11,400 vs. €13,755; not significant) than care-as-usual, with a comparable rate of 
adverse neonatal outcome (0.90 vs. 0.89; not significant), resulting in a more favorable 
cost-effectiveness for recurrence risk guided care. In contrast, from the societal per-
spective, recurrence risk guided care was both more costly than care-as-usual (costs 
€35,283 vs. €32,729; not significant) and less effective in terms of QALYs (0.75 vs. 0.81; 
not significant).  
Conclusions 
From a hospital perspective, the impact on costs of implementing recurrence risk guid-
ed care in the next pregnancy to formerly preeclamptic patients is modest. However, 
from the societal perspective, recurrence risk guided care is associated with a shift 
from hospital costs to health care costs outside the hospital while also reducing health-
related quality of life.  
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Introduction 
Preeclampsia (PE) and the HELLP syndrome affect 2 to 7% of all pregnancies in nullipa-
rous women (1). These disorders may have long-term consequences for mother and 
child (2, 3). Particularly women with a history of PE/HELLP are at increased risk of re-
currence in their next pregnancy (4). There is no consensus about the clinical manage-
ment in the next pregnancy. As a result, follow-up and counseling vary widely per 
country, center, gynecologist and patient, with care largely determined by subjective 
criteria, and thus possibly not cost-effective. Since only part of these women develop 
recurrent disease in their next pregnancy, the management in that pregnancy may 
benefit from differentiating between those at low and at high recurrence risk. We 
developed a prediction model that enables tailoring the intensity of care to each pa-
tient’s estimated recurrence risk (5). Particularly low-risk patients are likely to benefit 
from this type of risk stratification, by averting superfluous surveillance and associated 
usage of health care resources. It follows that recurrence risk guided care (RGC) has 
the potential to reduce the costs of care without compromising pregnancy outcomes 
and quality of life.  
 
This study was designed to explore whether RGC was more cost-effective than care-as-
usual (CAU) in the clinical management of these women in their next pregnancy. To 
this end, we developed a model to predict recurrent early-onset PE/HELLP and com-
pared the cost-effectiveness of RGC with that of CAU in 311 newly pregnant former 
patients.  
Materials and methods 
This study is part of the so-called “PreCare study” which has been detailed elsewhere 
(6). The study consisted of two phases. In the first phase, we followed CAU patients 
from their first outpatient visit in pregnancy until 3 months postpartum. An additional 
group had been also managed by CAU in the past. We retrieved the (anonymized) data 
from this group retrospectively from the hospital information system. In the second 
phase, we introduced our prediction model into clinical practice.  
 The patient population consisted of pregnant women over 18 years of age, who 
had developed early-onset (<34 weeks) PE/ HELLP in their previous pregnancy and had 
their first consultation at the outpatient clinic before the 20th week of pregnancy. We 
excluded women with severe co-morbidity (diabetes mellitus, systemic lupus erythe-
matosus, renal disease, cardiac disease and the anti-phospholipid syndrome) or who 
had delivered at term (> 37 weeks) in their previous pregnancy. The study was ap-
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proved by the Medical Ethical Review Board of the Maastricht University. We matched 
each enrolled patient in RGC to a patient receiving CAU patient for age category (10-
year age groups: 20-30; 31-40; 41-50), center and pregnancy length in the previous 
pregnancy (<34 weeks and between 34 and 37 weeks). 
 In CAU, obstetricians managed their patients in whatever manner they deemed 
appropriate. RGC consisted of two monitoring protocols. The Medium Care (MC) and 
High Care (HC) protocol contained 9-11 and 14-16 outpatient visits, respectively. Pa-
tients allocated to HC were allowed to undergo additional diagnostic tests. Activities in 
addition to those described in the protocols were registered. 
 
We performed an economic evaluation with a time horizon of one year. We calculated 
two incremental cost-effectiveness ratios (ICERs) expressing 1) hospital cost per pre-
vented adverse neonatal outcome (child outcome), from the hospital perspective, and 
2) societal cost per Quality Adjusted Life Year, i.e. QALY (maternal outcome), from the 
societal perspective. An adverse outcome was defined as an admission to the neonatal 
intensive care unit (NICU) or perinatal mortality. If a newborn required NICU admission 
for at least one day or died, this was coded as 0 (i.e. a negative outcome); in all other 
cases, the outcome was coded as 1 (i.e. a positive outcome). The difference in propor-
tions of positive outcome reflects the number of adverse cases prevented. For calcula-
tion of the ICER, we subtracted the costs of a NICU admission from the total costs to 
avoid double-counting. 
 QALYs were estimated using a generic health-related quality of life instrument, 
the EuroQol (EQ-5D) (7). For each health state, a utility score can be computed, based 
on preferences from a general Dutch population (8). The EQ-5D was sent together with 
the cost questionnaires to all women followed prospectively. Cost analyses were per-
formed according to the Dutch guideline (9). Costs were expressed in 2011 Euros. If 
necessary, costs prices were actualized to 2011 using the Dutch Consumer Price Index 
(10). Health care-related unit prices were obtained from published guidelines (9, 11). 
Costs per patient were calculated by multiplying volumes with unit prices of the re-
sources used (9). 
 The analysis from the hospital perspective only included costs made within the 
hospital. The data on individual hospital resource use were retrieved from the hospital 
information systems. The analysis from the societal perspective also included costs 
outside the hospital by means of retrospective cost questionnaires with a recall period 
of 3 months. The costs of prescription drugs used by the participants were obtained 
from the Dutch pharmacotherapeutic compass (12). Productivity costs due to sick 
leave were calculated using the friction costs method (11).  
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Statistical analysis 
Analyses were performed based on intention to treat. The dataset was checked for 
completeness and validity by consultation of the research nurses in the hospitals in 
case of inconsistencies. We employed single imputation to replace missing values (13), 
followed by bootstrapping to determine the 95% confidence intervals around cost-
differences between RGC and CAU and to quantify the degree of uncertainty around 
the ICER. Based on bootstrapped cost-effectiveness results (data not shown), cost-
effectiveness acceptability curves were constructed, showing the probability that RGC 
is cost-effective using a range of ceiling ratios (14). Bootstrapping was performed using 
Excel 2010. Other analyses were performed using SPSS, version 20.0 for Windows 
(SPSS INC 2012). Additionally, subgroup and sensitivity analyses were performed. For 
the hospital perspective, we evaluated the effect on the cost-effectiveness ratio of age 
(< or ≥ the median), the gestational age at birth in the previous pregnancy (<34 weeks 
or between 34 and 37 weeks) and whether the previous pregnancy resulted in the 
birth of a small-for-gestational-age (SGA) infant. For the societal perspective, we also 
performed analyses for a low vs. high anxiety group (< or ≥ the median), a low vs. high 
depression group (< or ≥ the median) and for signs vs. no signs of posttraumatic stress 
disorder at baseline (< or ≥ the median). Besides, differences between RGC and CAU 
may partly result from differences in unit prices per admission day between university 
and non-university hospitals. In the analysis from the societal perspective, 93% (CAU) 
and 84% (RGC) of the admissions were in university hospitals. This potential effect was 
tested by applying the same unit prices irrespective of type of hospital. In the analysis 
from the hospital perspective, about the same proportions of admissions in CAU and 
RGC were in a university hospital. Therefore, we refrained from this sensitivity analysis 
in the analysis from the hospital perspective. An imbalance in baseline utility scores 
between RGC and CAU can result in a misleading incremental cost-effectiveness ratio. 
Therefore, we adapted the utility scores in one group by correcting for the baseline 
difference between the two groups (15). 
Results 
Patient population 
In the analysis from the hospital perspective, we included 311 patients (152 CAU and 
159 RGC, 37 receiving HC and 122 MC). For the analysis from the societal perspective, 
only prospectively included patients were considered (n= 207). Of these, 185 had re-
turned at least one questionnaire and were included in the analyses (45 CAU and 140 
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RGC, 34 receiving HC and 106 MC). Baseline characteristics of the 185 women are 
presented in Table 1.  
 
Table 1: Characteristics of the selection of women for the cost-effectiveness analysis 
 
  
Recurrence risk 
guided care1,2 
 
(n=159) 
Care-as-usual 
total1 
 
 (n=152) 
Care-as-usual 
prospectively 
included1,2 
 (n=48) 
Care-as-usual 
retrospectively 
included1 
 (n=104) 
 
 
p-value
Maternal characteristics         
Maternal age at conception (y) 30.92 (4.44) 31.14 (5.01) 32.37 (5.26) 30.57 (4.81) 0.68 
Body mass index (kg/m2) 25.58 (6.01) 26.33 (5.58) 25.33 (4.88) 27.26 (6.06) 0.32 
Gravidity 2.52 (0.84) 2.59 (1.35) 2.96 (1.98) 2.42 (0.88) 0.56 
Parity 1.11 (0.38) 1.15 (0.57) 1.17 (0.75) 1.15 (0.47) 0.41 
Treated in      
 University hospital, n (%) 135 (84.9) 132 (86.8) 45 (93.8) 87 (83.7) 0.62 
 Non-university hospital, n (%) 24 (15.1) 20 (13.2) 3 (6.3) 17 (16.3)  
Characteristics of previous pregnancy      
Gestational age (weeks) 31.12 (3.79) 31.11 (3.56) 31.18 (3.12) 31.08 (3.75) 0.99 
Birthweight (g) 1409.29 (729.49) 1432.55 (734.49) 1404.02 (716.48) 1467.79 (764.53) 0.82 
 Low birthweight (<2500 g) 130 (81.76) 70 (46.05) 38 (79.17) 32 (30.77)  
 Very low birthweight (<1500 g) 92 (57.86) 45 (29.61) 28 (58.33) 17 (16.35)   
Data are given as mean ± SD or as percentages 
1) Hospital perspective 
2) Societal perspective 
Hospital perspective 
Our analyses showed that RGC was not associated with a higher rate of adverse neona-
tal outcome, indicated by comparable proportions of prevented adverse neonatal 
outcome in the subgroups receiving RGC (90%) and CAU (89%). In RGC, the rate of 
adverse neonatal outcomes was slightly higher in HC (14%) than in MC (9%).  
 Mean hospital costs per patient did not differ significantly between women receiv-
ing RGC and those receiving CAU (mean difference €305; 95% CI from -€4,960 to 
€4,456). Neither maternal outpatient visits (16 and 17) nor admission days (7 and 8) 
differed appreciably between RGC and CAU (Table 2). The same applied to the total 
hospital costs for the mother (mean difference €468; 95% CI from -€1,413 to €532) and 
the child (mean difference €163; 95% CI from -€4,024 to €4,532). Infant costs in RGC-
HC (€13,016) were almost twice as high as those in RGC-MC (€6,389), without an ap-
preciable difference in maternal costs (HC €7,211 and MC €7,638). 
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For calculation of the ICER, we subtracted the costs associated with NICU admissions 
from total hospital costs, resulting in mean hospital costs of €11,400 for RGC vs. 
€13,755 for CAU. Calculation of the point estimate of the ICER was not needed as RGC 
is dominant over CAU (less costly and more effective). See Table 4. 
 The cost-effectiveness acceptability curve illustrates an 80-95% probability of RGC 
being more cost-effective than CAU (Figure 1).  
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Figure 1: Cost-effectiveness acceptability curve: costs per adverse outcome child prevented 
Societal perspective 
The utility scores at baseline and at follow-up were slightly higher in CAU than in RGC 
(0.03), resulting in lower QALYs in RGC than in CAU (0.75 and 0.81, respectively). In 
RGC, HC patients reported consistently higher utilities than MC patients at all meas-
urement moments resulting in higher QALYs (0.78 and 0.75 respectively).  
 The mean societal costs per patient in RGC were not significantly different from 
the costs per patient in CAU (bootstrap mean difference €2,722; 95% CI from -€4,968 
to €9,993). Taking only hospital costs into account, RGC differed from CAU by resulting 
in less total costs for mother and child (Table 3). Conversely, RGC tended to be associ-
ated with higher total costs outside the hospital than CAU (€2,651; 95% CI from -
€1,463 to €6,361), of which the health care component was significantly different 
(bootstrap mean difference €1,799; 95% CI from €527 to €2,973). In RGC, hospital 
costs for HC and MC were €21,180 and €14,017 respectively, with health care costs 
outside the hospital being €5,003 and €5,574. Calculation of the point estimate of the 
ICER from the societal perspective was not necessary as RGC is inferior to CAU (i.e. 
more costly and less effective). 
 Irrespective of the ceiling ratio, RGC has a low probability of being cost-effective, 
ranging from 30% to 5% (Figure 2). These results indicate that, from the societal per-
spective, RGC is not cost-effective.  
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Figure 2: Cost-effectiveness acceptability curve: costs per QALY 
 
Subgroup analyses from the hospital perspective (Table 4) revealed that RGC was more 
cost-effective in older women, who in their previous pregnancy had given birth after 
the 34th week to a non-SGA infant. For almost all other subgroups, RGC was less costly, 
though also slightly less effective. Subgroup analyses from the societal perspective 
indicated that, for most subgroups, RGC was less cost-effective than CAU. Exclusion of 
an outlier (extremely high neonatal costs, i.e. €221,070), applying the same unit prices 
to university and non-university hospitals and using the mean difference adjustment 
method for baseline utilities did not change our conclusion about RGC being more 
costly than CAU. Overall, subgroup and sensitivity analyses show a clear trend towards 
more costs and lower QALYs in patients receiving RGC. 
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Comment  
This study was designed to investigate whether RGC is more cost-effective than CAU in 
the next pregnancy of women whose previous pregnancy had been complicated by 
early-onset PE/HELLP.  
 The base-case results support the concept that RGC leads to lower maternal hos-
pital-related costs and thus, is more cost-effective than CAU from a hospital perspec-
tive. Conversely, from the societal perspective, RGC was less cost-effective than CAU, 
due to lower reported quality of life and higher costs outside the hospital. The latter 
seemed to result from patients in the MC subgroup, visiting more often other care 
providers than CAU patients. Utilities were consistently higher in CAU than in RGC at all 
measurement moments, contributing to higher QALYs in CAU. In the RGC group, both 
HC and MC subgroups reported lower utilities than CAU at all four measurement mo-
ments. Bootstrap results showed that RGC was less effective in terms of QALYs (99% of 
replications), and led to higher societal costs.  
 To our knowledge, this study is the first that evaluates the economic effects of 
recurrence risk-guided interventions in pregnant women who experienced PE/HELLP in 
their previous pregnancy. Multi-parameter tools for the prediction of recurrent early-
onset PE/HELLP have only been reported recently (16). Besides, no evidence-based 
guidelines for the management of this particular group of former patients are availa-
ble. The results of the PreCare study were disappointing. Our prediction model dis-
criminated poorly (17). Nevertheless, implementing the model into clinical practice 
had no appreciable effect on the maternal and perinatal outcome (18). Adherence to 
the HC and MC protocols was disappointing, as reflected in the wide variation in the 
number of visits to the outpatient clinic in the RGC group. The intensity of the clinical 
management in these patients is influenced by the experience and expertise of the 
obstetrician, and confidence of the patient in herself and her doctor. Besides, also the 
unpredictability in clinical presentation of PE/HELLP plays a role, as it may vary widely 
in severity and rate of deterioration. We explored several patient related factors (i.e. 
recurrence of PE/HELLP, depression, anxiety, posttraumatic stress, QALY, the level of 
satisfaction) and could not detect a relation with the (excess) number of outpatient 
visits (data not shown). Nevertheless, cost-effectiveness analyses from both perspec-
tives confirm that hospital costs were lower in RGC than in CAU. Particularly the costs 
outside the hospital boost the total costs for RGC relative to those for CAU. This may 
be related to the (perceived) lower allowance for outpatient visits in RGC driving them 
to seek support and/or reassurance from alternative caregivers. This may also have 
caused the lower health-related quality of life in RGC compared to CAU. This problem 
may be solved by creating an easy-accessible back-up system for patients, consisting of 
a same-day-call-back-service, e.g. by specialized nurse practitioners.  
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The study had various limitations. Some variables had missing values. These variables 
consisted of predictor variables, indicators of intensity of care, indicators of cost-
effectiveness and, in some cases, important outcome variables. Omitting patients with 
one or more missing variables from the analysis would have reduced statistical power 
markedly, potentially introducing selection bias. In the original PreCare dataset we 
measured a wide range of variables that were included in the imputation model, in-
creasing the likelihood of valid predictions of replacements for missing values. There-
fore, we are confident that the regression imputation we used adds to the accuracy of 
our results. Finally, the datasets available for data retrieval from retrospectively as-
sessed patients in the CAU group were often incomplete and/or contained errors. 
Some variables may have been underestimated because of incomplete registration in 
the medical records (information bias). In addition, because they were included retro-
spectively, these women could not fill out questionnaires.  
 We conclude that, from a hospital perspective, it would be cost-effective to offer 
previous preeclamptic women RGC instead of CAU. However, from a societal perspec-
tive, RGC is not cost-effective, which is due to a lower health-related quality of life and 
a shift to health care consumption outside the hospital. 
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Abstract 
Background 
It has become evident that patient satisfaction is an important issue to consider when 
optimising the (cost-)effectiveness of a health care innovations, as patients’ opinions 
will help shape, improve and implement the innovation. This study aimed to investi-
gate the level of satisfaction with recurrence risk guided care in pregnant women who 
had suffered from preeclampsia or HELLP syndrome in their previous pregnancy. Other 
objectives were to determine which factors contribute to the level of satisfaction and 
whether level of satisfaction has an influence on protocol adherence. 
Methods 
This patient satisfaction study is part of the larger PreCare study, investigating the 
effectiveness and cost-effectiveness of recurrence risk guided care versus care as usu-
al. Patients were treated in six university hospitals and seven large non-university ter-
tiary referral hospitals in the Netherlands between 2008 and 2012. Patient satisfaction 
was measured by the Patient Satisfaction Questionnaire (PSQ III) at baseline and 10 
days postpartum. Based on Crow’s holistic model of satisfaction, multivariate regres-
sion analyses were performed to investigate which factors (i.e. baseline level of satis-
faction, level of care (i.e. High Care or Medium Care), socio-demographic variables, 
health state at baseline, previous experiences and expectations) contribute to the level 
of satisfaction 10 days postpartum and which subscales of the PSQ III contribute to 
protocol adherence. 
Results 
Patient satisfaction scores were high on all subscales of the PSQ III. Factors that ex-
plained variation in patient satisfaction were level of care, psychological health state at 
baseline, expectations and baseline patient satisfaction score. Protocol adherence was 
poor and after controlling for other factors, only associated with the “communication” 
subscale. 
Conclusion 
Although we lack a comparison with care-as-usual, our findings indicate that, overall, 
patients were satisfied with recurrence risk guided care. Satisfaction scores were mod-
erately well explained by factors contained in Crow’s model. Patient satisfaction was, 
however, a poor predictor of protocol adherence, probably because health care pro-
viders’ and organisational characteristics are important co-determinants of protocol 
adherence. 
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Background 
Quality of care has gained greater prominence in recent years and there is a growing 
body of evidence in this field of research [1-3]. Quality of care can objectively be as-
sessed by examining clinical practice in terms of process and outcome indicators and 
subjectively by obtaining patient experience indicators, like patient satisfaction [2, 4, 
5]. Examining quality of care through the patients’ eyes can reveal important infor-
mation, because professional and expert views about the care provided can vary 
markedly from patient judgements [6, 7]. Monitoring patient satisfaction is important 
because if the quality of the care provided is evaluated regularly, problem areas can be 
isolated and ideas for improvement can be generated [8, 9]. Furthermore, as satisfied 
patients are more positive about their situation, they tend to respond better to treat-
ment and are more compliant and cooperative, improving their health outcomes [10-
12]. 
 Women with high risk pregnancies have been a particular target group for investi-
gating patient satisfaction. Pregnancy in this patient group can be a stressful and dis-
satisfying experience which generally results in increased health care consumption [13-
19]. Furthermore, previous studies have shown that the quality of prenatal care is an 
important determinant of pregnancy outcome [20, 21]. 
 The focus of this paper is on patient satisfaction in a sample of pregnant women 
with a history of preeclampsia (PE) or HELLP syndrome who participated in a multicen-
tre before-after study investigating the effectiveness and cost-effectiveness of recur-
rence risk guided care (RGC) versus care-as-usual (CAU), the PreCare study. Details on 
the design of the study have been reported previously [22]. For RGC, we developed a 
model for the prediction of recurrent PE/HELLP in the next pregnancy for formerly 
preeclamptic women. Based on the prediction model, women were stratified into 
subgroups to be allocated to Medium Care (MC) or High Care (HC), according to their 
actual risk profile. In this study, we measured patient satisfaction with RGC. Patient 
satisfaction with risk-adjusted antenatal care is of interest to practitioners and policy 
makers because user acceptability will optimise the (cost-)effectiveness of RGC, e.g. 
through protocol adherence, and will enhance its broader implementation. Further-
more, areas for improvement can be identified. 
 
In this study, we addressed the following research questions: 
1. What is the level of satisfaction of patients who receive RGC? 
2. Which factors contribute to the level of satisfaction? 
3. Does level of satisfaction have an influence on protocol adherence? 
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Methods 
Recruitment, design and sample 
This patient satisfaction study is part of the larger before-after PreCare study. The 
PreCare study is embedded in the Dutch Obstetric Consortium, a collaboration of hos-
pitals in the Netherlands [23]. 
 Between 2008 and 2012, pregnant women were recruited through six university 
hospitals and seven large non-university tertiary referral hospitals in the Netherlands. 
Participants were eligible if they were 18 years and older, had PE and/or HELLP syn-
drome in their previous pregnancy and visited the outpatient clinic until 20 weeks of 
pregnancy. Exclusion criteria were severe co-morbidity (including diabetes mellitus, 
systemic lupus erythematosus, renal disease, cardiac disease or anti-phospholipids 
syndrome) and giving birth after 37 weeks gestational age in the previous pregnancy. 
All eligible patients received detailed information about the study. 
 The study protocol was approved by the Medical Ethical Review Board of the 
Maastricht University Medical Centre (NL). All participating centres signed a local fea-
sibility declaration, according to the Dutch law and regulations, prior to inclusion of the 
first patient. 
A holistic model of patient satisfaction 
Despite the increased focus on patient satisfaction in recent years, there is still no 
agreement on its definition. Hulka et al., 1970 defined satisfaction as the patient’s 
attitudes toward physicians and medical care [24]. Another definition of patient satis-
faction is the attitudinal response to value judgments that patients make about their 
clinical encounter [25]. Linder-Pelz defined patient satisfaction as evaluations of dis-
tinct dimensions of the health care [26]. In this paper, we use the latter definition of 
patient satisfaction. 
 Several approaches have been used to try to identify the factors contributing to 
satisfaction, e.g. approaches based on expectation, approaches based on health ser-
vices attributes and economic approaches [9]. Holistic approaches attempt to incorpo-
rate all influences on satisfaction and thereby to provide a comprehensive framework 
for exploring interactions between variables that affect patients’ evaluations [9]. Crow 
et al., 2002 [9] presented a holistic model, adapted from Strasser and Davis (1991) [27] 
and Strasser et al. (1993) [28]. 
 As a conceptual framework for answering our research questions, we made use of 
Crow’s holistic model of patient satisfaction [9]. According to this model, patients ex-
perience individual stimuli such as actions, attitudes and appearances of human re-
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sources, the physical environment and organisational aspects of care (Box A). Then, 
perceptions are created through cognitive and affective processes (Box B), which are 
specific to individual patients, reflecting their particular individual characteristics (Box 
C). (Dis)satisfaction is viewed as a reflection of the difference between what is ex-
pected and what is perceived to have been delivered. If the expectations exceed the 
experiences, the patient will be dissatisfied; if the experiences exceed the expecta-
tions, the patient will be satisfied [9]. 
 Satisfaction is an individual attitudinal response to the value judgments formed 
before (Box D). Satisfaction or dissatisfaction has consequences for both the patient 
and the provider (Box E). On patient level, satisfaction is linked with adherence to 
medical advice, self-care, and hence with health outcomes. Furthermore, satisfied 
patients will use the service again and recommend it to others. The model described 
above is shown in Figure 1. 
 
 
Figure 1: Holistic model of satisfaction with health care, adapted from Crow et al., 2002 [9] 
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Procedures and intervention (Box A) 
At the first visit at the outpatient clinic, after written informed consent was obtained, 
the risk of severe recurrent PE/HELLP was calculated. For risk calculation, an easily 
applicable computer programme was developed and made available for the participat-
ing gynaecologists and research nurses. On the basis of the predicted risk, the patient 
was allocated to either the Medium Care or the High Care protocol. 
 The Medium Care protocol consisted of 9-11 outpatient clinic visits at (8, 12), 16, 
20, 24, 28, 32, 36, 38, 39 and 40 weeks gestational age. The High Care protocol con-
sisted of 14-16 outpatient clinic visits at (8, 12), 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 
36, 38, 39 and 40 weeks gestational age. In the High Care group, the patient additional-
ly underwent a series of diagnostic tests, which consisted of measurements in urine 
(e.g. microalbuminuria, creatinine, and protein), measurements in blood (e.g. haemo-
globin, platelet count, and glucose), and assessment of the Doppler flow velocity pro-
file in both uterine arteries at 20 weeks. Ambulatory blood pressure monitoring was 
suggested but not obligatory. Activities other than, or additional to those described in 
the Medium Care and High Care protocols (such as intercurrent admissions and addi-
tional outpatient visits) were also recorded. 
Measurement of patient satisfaction (Box D) 
In order to assess patient satisfaction, the Dutch version of the validated Ware’s Pa-
tient Satisfaction Questionnaire III (PSQ III) was used, which was filled out at baseline 
and 10 days postpartum. The PSQ III measures the multiple concept of patient satisfac-
tion and incorporates “general satisfaction”, “technical quality”, “interpersonal as-
pects”, “communication”, “financial aspects”, “time spent with doctor” and “ac-
cess/availability/convenience” [29]. In the Dutch version, the financial items are omit-
ted because these are not appropriate for the Dutch socialised system (i.e. questions 4, 
10, 14, 19, 24, 27, 32 and 44). As a result, the questionnaire consists of 43 favourably 
and unfavourably worded statements, in which respondents are asked to indicate their 
agreements with the statements with respect to the care they received. The question-
naire was scored with five response categories ranging from 1 (strongly agree) to 5 
(strongly disagree). Answers to favourably worded items were recoded so that higher 
scores indicate greater satisfaction. Sum scores were calculated for the six subscales 
and subsequently transformed into a 100-point scale so that subscale scores are di-
rectly comparable to one another despite different numbers of items on each scale. 
 As an additional aspect for rating satisfaction with the given care according to the 
monitoring protocols, a specific questionnaire was developed inspired by the Women’s 
questionnaire in the antenatal care trial performed by the World Health Organization 
[30]. At baseline, this PreCare satisfaction questionnaire contained seven statements 
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concerning the expectations regarding RGC regarding the number of outpatient visits 
(2 statements), the time between visits (3 statements) and RGC (3 statements). Pa-
tients were asked to indicate on a 5-point Likert scale whether they fully agreed (1) or 
fully disagreed (5) with each of the statements. Finally patients were asked to indicate 
the overall satisfaction regarding antenatal care on a scale from 1 (very dissatisfied) to 
10 (very satisfied). Answers to favourably worded items were recoded so that higher 
scores indicate more positive expectations. Subsequently, a sum score was calculated. 
The sum score ranges from 7 to 35 with higher scores reflecting more positive expecta-
tions. The questionnaires were sent to the patients’ homes and requested to be re-
turned by postal mail. 
Individual characteristics (Box C) 
Selection of patient characteristics that might affect patient satisfaction was based 
upon Crow’s model and availability of data from the PreCare study. The patient varia-
bles that were considered in this patient satisfaction study can be grouped into four 
areas: socio-demographic factors, health state at baseline, previous experiences and 
expectations. The first category, socio-demographics, includes information about age 
(in years), country of birth (Netherlands or other) and educational level (low: primary, 
junior secondary, senior secondary; and high: higher professional or university educa-
tion). This information was obtained by a questionnaire sent at approximately 29 
weeks of pregnancy. Additionally, information about health state at baseline (i.e. 
health-related quality of life and psychopathology) was collected. At inclusion, all pa-
tients completed a questionnaire on health-related quality of life and were evaluated 
for DSM-IV depressive, anxiety and posttraumatic stress disorder (PTSD) symptoms. 
Health-related quality of life was measured with the EuroQol (EQ-5D) [31]. The de-
scriptive system of the EQ-5D consists of five dimensions (mobility, self-care, daily 
activities, pain/discomfort, depression/anxiety). Each dimension has three response 
options: no problems (1), some problems (2), severe problems (3), leading to 243 pos-
sible health states. For each health state, a utility score can be computed, based on 
preferences from a general Dutch population, i.e. the Dutch tariff. Depressive, anxiety 
and posttraumatic stress disorder (PTSD) symptoms were measured with the Beck 
Depression Inventory (BDI) [32], the State Trait Anxiety Inventory (STAI) [33] and the 
PTSD Symptom Scale [34] respectively. Scores on the depression scale range from 0 to 
63. Higher scores correlate with greater depression: 0-9 minimal depression, 10-18 
mild depression, 19-29 moderate depression, 30-63 severe depression. Scores on the 
anxiety scale range from 20 to 80. Higher scores correlate with greater anxiety. Scores 
on the PTSD scale range from 0 to 51. A total score higher than 13 indicates a likely 
presence of PTSD. Previous experiences (characteristics of the previous pregnancy: 
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gestational age at delivery and small-for-gestational age) were collected from patient 
files and recorded in online Case Report Forms (CRFs), which were specifically designed 
for the PreCare study. The last group of variables, called “expectations”, was measured 
by the PreCare satisfaction questionnaire, and we corrected also for PSQ III baseline 
scores. Values, beliefs and personality were not measured. 
Protocol adherence (Box E) 
Data on actual care received, i.e. number of hospital visits and diagnostic measure-
ments, were recorded in online CRFs. First, we calculated patient-level protocol adher-
ence scores by summing the actual number of outpatient visits. The required number 
of outpatient visits according to the MC or HC protocol was adjusted for gestational 
age at delivery, since women with preterm deliveries are likely to have less outpatient 
visits than women with term deliveries. Then, we compared the actually received 
number of visits per patient with the adjusted number of visits described in the MC or 
HC protocol (depending on the patient’s risk). Protocol adherence was a continuous 
variable. The adherence score is positive for the number of times the patient had had 
an outpatient visit exceeding the number of visits described in the protocol; the ad-
herence score is zero if the number of times the patient had a visit is lower than or 
equal to the number of visits described in the protocol. 
Statistical analysis 
Descriptive statistics, including frequencies, percentages, means and standard devia-
tions (SDs), were used to describe the population at baseline. Women who did not 
return any patient satisfaction questionnaire were compared with women who re-
turned at least one patient satisfaction questionnaire with respect to important varia-
bles (maternal characteristics and characteristics of the previous pregnancy) using a 
Chi-square test for categorical variables and a t-test for continuous variables. Missing 
values within the survey’s subscales were replaced using single imputation. 
 In order to investigate which factors contribute to the level of satisfaction at 10 
days postpartum, candidate variables (i.e. HC/MC, sociodemographic variables, health 
state at baseline, previous experiences and expectations) were identified by including 
them in a multivariate regression model using a backward selection procedure. This 
automated backward stepwise procedure implied dropping statistically non-significant 
independent variables from the model using a significance level of α= 0.10. The varia-
bles “education” and “country of birth” had missing values in 21 patients; both varia-
bles were statistically non-significant among the 63 patients without missing values. 
The final model was therefore produced among patients with and without missing 
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values on these variables (n=84) by forcing all variables into the model that were sta-
tistically significant among the smaller sample. Regression coefficients in the smaller 
and larger sample were similar, indicating the robustness of the results. 
 In order to investigate which subscales of the PSQ III contribute to protocol adher-
ence, all subscales (i.e. “general satisfaction”, “technical quality”, “interpersonal as-
pects”, “communication”, “time spent with doctor” and “access/availability/-
convenience”) were introduced into a multivariate regression model and maintained 
or dropped using backward selection (α=0.10). We controlled for confounding varia-
bles (see previous regression analysis: HC/MC, sociodemographic variables, health 
state at baseline, previous experiences and expectations). Again, regression coeffi-
cients in the smaller and larger sample were similar. Collinearity between the variables 
in the model was assessed by examining the tolerance and variance inflation factor for 
each independent variable. Normality of the residuals was checked by use of a normal 
probability plot of the residuals. Significance tests of all other analyses were two-tailed 
and α was set at 0.05. All analyses were performed using SPSS 20.0. 
Ethical considerations 
This study has been approved by the ethical committee of the University Hospital 
Maastricht (Ref.no. MEC 07-2-078). A total of six academic and seven non-academic 
hospitals participate in the study; all hospitals completed the obligatory feasibility 
assessment procedure successfully. Informed consent was obtained from all patients 
prior to enrolment into the study. 
Results 
Patients 
In total, 159 RGC patients participated in the larger PreCare study. The first RGC pa-
tient was included in June 2009 and the last one in May 2012. We introduced the pa-
tient satisfaction questionnaires some time after commencement of the study, the first 
patient satisfaction questionnaire was filled out in January 2010. Of the total sample of 
159, 103 patients were offered the satisfaction questionnaires. Eighty-four women 
(81.6%) returned at least one satisfaction questionnaire and were included in the pre-
sent study. Baseline characteristics of the women are presented in Table 1. There were 
no relevant differences between respondents and non-respondents with respect to 
maternal characteristics and characteristics of the previous pregnancy, except for 
country of birth. 
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Table 1: Characteristics of women treated according to RGC 
  Respondents 
 (n=84) 
Non-respondents 
(n=19) 
Maternal characteristics    
Maternal age at conception (yrs) 31.4 (4.5) 31.7 (5.2) 
Body mass index (kg/m2) 25.7 (6.2) 25.4 (5.3) 
Gravidity 2.5 (0.8) 2.5 (0.6) 
Parity 1.1 (0.4) 1.2 (0.5) 
Hypertension, n (%) 29 (34.5) 5 (26.3) 
Country of birth   
Netherlands, n (%) 58 (69.1) 9 (47.4) 
Other, n (%) 5 (6.0) 4 (21.1) 
Missing, n (%) 21 (25.0) 6 (31.6) 
Educational level   
Low, n (%) primary school, junior/senior secondary 38 (45.2) 7 (36.8) 
High, n (%) higher professional, university 25 (29.8) 6 (31.6) 
Missing, n (%) 21 (25.0) 6 (31.6) 
Utility score baseline  0.8 (0.3) 0.8 (0.3) 
PTSD score baseline 9.1 (6.7) 7.3 (6.9) 
Anxiety score baseline 46.8 (11.4) 46.2 (10.6) 
Depression score baseline 10.3 (5.9) 9.2 (7.6) 
 
Characteristics of previous pregnancy  
Gestational age (weeks)  31.2 (3.7) 31.8 (4.1) 
PE, n (%)  73 (86.9) 17 (89.5) 
HELLP syndrome, n (%)  50 (59.5) 9 (47.4) 
Eclampsia, n (%)  3 (3.6) 1 (5.3) 
IUFD, n (%)  8 (9.5) 3 (15.8) 
Birth weight (gr) 1398.7 (721.9) 1574.7 (840.8) 
IUGR, n (%)  30 (35.7) 9 (47.4) 
Data are given as mean ± SD or as percentages 
* Significant differences 
The level of satisfaction 
Table 2 shows the satisfaction scores measured 10 days postpartum, on a scale ranging 
from 0 to 100. Ten days postpartum all but one patient satisfaction score were in the 
top-25% of the PSQ III subscales. Lowest level of satisfaction was observed for the 
“time spent with doctor” subscale (score 74.22). This subscale includes items about 
whether doctors spend enough time or hurry too much when treating patients. The 
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highest level of satisfaction was reached for the subscale “interpersonal aspects” 
(score 87.32). 
 
Table 2: Average satisfaction scores 
 All patients (n=84) 
Mean (SD; range) 
General satisfaction 76.8 (14.9; 29.2-100.0) 
Technical quality 77.9 (12.2; 40.0-100.0) 
Interpersonal aspects 87.3 (10.3; 50.0-100.0) 
Communication 85.9 (11.0; 50.0-100.0) 
Time spent with doctor 74.2 (20.7; 12.5-100.0) 
Access/availability/convenience 75.2 (10.9; 33.3-97.9) 
Factors contributing to the level of satisfaction 
The results of the multiple regression analyses for those variables that were most pre-
dictive of patient satisfaction 10 days postpartum are shown in Table 3. 
 Patients with higher depression scores at baseline were more satisfied 10 days 
postpartum with “technical competence”, “interpersonal aspects”, “time spent with 
doctor” and “access”. Anxiety at baseline was negatively associated with the satisfac-
tion subscales “technical competence”, “interpersonal aspects”, “communication” and 
“access”. PTSD was associated with three satisfaction subscales “time spent with doc-
tor”, “interpersonal aspects” and “access”, although in an inconsistent manner. 
 Remarkably, level of care (HC/MC) was significantly related to the subscale “time 
spent with doctor” in that patients in the HC group were considerably more satisfied 
(11 points) than patients in the MC group. Expectations at baseline were positively 
associated with “general satisfaction” and satisfaction with “technical competence”, 
whereas PSQ III baseline scores were positively associated with “interpersonal aspects” 
and “time spent”. Overall, depression and PTSD at baseline can be said to have the 
most potent relationship to level of satisfaction, because of the largest standardised 
beta and the greatest significance (smallest p-value). 
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Table 3: Multivariate regression analysis of the association of various factors with patient satisfaction scores 
Dependent variable Explanatory variables Unstandardised 
B (SE) 
Standardised 
β 
p-value 
Gen. satisfaction Expectations baseline (PreCare satisfaction 
questionnaire sum score) 
 
0.637 (0.313) 0.219 0.045 
Techn. comp. Depression score baseline 0.320 (0.274) 0.155 0.246 
 Anxiety score baseline -0.262 (0.142) -0.244 0.069 
 Expectations baseline (PreCare satisfaction 
questionnaire sum score) 
 
0.498 (0.260) 0.208 0.059 
Interpers.asp. Depression score baseline 0.969 (0.279) 0.556 0.001 
 Anxiety score baseline -0.166 (0.117) -0.183 0.160 
 PTSD score baseline -0.614 (0.230) -0.401 0.009 
 Interpersonal aspects baseline score 
 
0.217 (0.075) 0.321 0.005 
Communication Anxiety score baseline 
 
-0.224 (0.104) -0.231 0.034 
Time spent HC/MC (0=HC; 1=MC) -11.004 (4.693) -0.247 0.022 
 Depression score baseline 1.441 (0.551) 0.421 0.011 
 PTSD score baseline -0.178 (0.461) -0.383 0.012 
 Time spent with doctor baseline score 
 
0.247 (0.105) 0.266 0.021 
Access Depression score baseline 0.432 (0.231) 0.235 0.066 
 Anxiety score baseline -0.352 (0.122) -0.369 0.005 
 PTSD score baseline 0.201 (0.087) 0.251 0.023 
 
Protocol adherence 
Table 4 shows the protocol adherence. Seventy out of 84 patients (83.3%) had more 
outpatient visits than prescribed in the HC or MC protocol (adjusted for gestational age 
at delivery). In most patients, the number of outpatient visits was exceeded with 1-5. 
The model of Crow, presented earlier, states that patient satisfaction is linked with, 
among others, adherence. After adjustment for confounding variables, only satisfac-
tion with “communication” appeared to be a predictor of adherence score in a back-
ward multivariate regression analysis assessing all patient satisfaction subscales 
(B=0.097; p=0.075). Being more satisfied with “communication” was significantly relat-
ed to more outpatient visits. However, only 16.4% of the variance in patient satisfac-
tion (R2) was explained by “communication”. 
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Table 4: Frequency of visits (percentage of patients) 
Non-adherent patients (n=70) 
Number of visits exceeding the number described in the protocol, n (%) 
1-5 visits 37 (44.0)  
6-10 visits 18 (21.4)  
> 10 visits 15 (17.9)  
Discussion 
Patient satisfaction is an important issue to consider when aiming to optimise the 
(cost-)effectiveness of a new treatment option, as patients’ opinions will help shape, 
improve and implement the treatment option [9]. Insight into patient satisfaction was 
therefore an important aspect of the PreCare study. Patient satisfaction scores seemed 
high in all subscales of the PSQ III as scores on most subscales were in the top-25%. 
High satisfaction scores do not imply that there is no room for improvement. In this 
study we observed differences between the satisfaction subscales. In general, patients 
were most satisfied with “interpersonal aspects” and ”communication”, and least 
satisfied with ”time spent” and ”access”. Several studies have used (parts of) the PSQ 
III. The reported satisfaction scores in other studies may be used as some kind of a 
benchmark for this study, although it should be noted that they apply to different 
populations and care settings. The study of Hagedoorn et al. in 2,594 Dutch cancer 
patients reported mean satisfaction scores on “technical competence” of 78.2 and 
80.3 on “access” [35]. Another Dutch study in 299 cancer patients reported mean 
scores on “general satisfaction” of 76.4 (telephone follow-up treatment arm) and 75.3 
(hospital follow-up treatment arm), on “technical competence” of 75.8 and 73.7, on 
“interpersonal aspects” of 80.5 and 78.7 and on “access” of 76.4 and 73.3 [36]. Thomas 
et al., 2009 found in 653 cancer patients in Canada mean “general satisfaction” scores 
ranging from 55.5 to 69.3, depending on ethnicity and other demographic characteris-
tics [37]. The study of Marshall et al., conducted in 417 patients with significant symp-
toms of depression and 535 with chronic physical health conditions in the United 
States, found mean scores on “technical competence” of 64.05 and 70.83, mean scores 
on “interpersonal aspects” of 68.90 and 76.12, mean scores on “communication” of 
66.91 and 74.39, mean scores on “time spent” of 58.39 and 66.80 and mean scores on 
“access” of 65.95 and 73.01 [38]. These figures indicate that, in general, our patient 
group was quite satisfied in comparison to those of other studies. Studies conducted in 
the United States and Sweden showed a higher patient satisfaction with gynaecology-
obstetrics compared with other specialties [39, 40]. 
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Besides examining the level of satisfaction, more importantly, this study provides in-
sight in factors relating to patient satisfaction. The most consistent finding in the litera-
ture regarding these factors has been related to age. Older patients tend to be more 
satisfied than younger patients [40-43]. In our study, however, age did not contribute 
to patient satisfaction. This finding is possibly due to the small variance in age in our 
sample of pregnant women (between 20-40 years). Furthermore, being a member of a 
minority group is associated with lower rates of satisfaction [44]. Less educated indi-
viduals and those with a lower socioeconomic status tend to be less satisfied [45]. In 
this study, “country of birth” and “education” were not included in the final regression 
model because of the large number of missing values on these variables. Current evi-
dence also shows that patients with a lower health state report more problems with 
the health care system [46]. Some studies have shown that poorer satisfaction is asso-
ciated with depression, as is having a psychiatric diagnosis such as posttraumatic stress 
disorder [47-49]. Although some studies have reported associations between these 
individual characteristics and patient satisfaction scores, the evidence has been gener-
ally inconclusive [9]. Patients’ expectations are believed to be another major determi-
nant of satisfaction with health care [50, 51]. It is suggested that patients with lower 
expectations and patients with a greater number of met expectations tend to be more 
satisfied [8]. In this study, it was found that patients with more positive expectations 
are more satisfied, which indicates that their expectations had been met. It is im-
portant to highlight that various factors previously reported to influence patient satis-
faction did not contribute to the variation in patient satisfaction in this study. Only 
patients’ expectations, baseline psychological health state and being assigned to HC or 
MC had a significant impact on aspects of satisfaction. Remarkably, whether women 
had been assigned to either HC or MC was significantly related to satisfaction regard-
ing “time spent with doctor”. Patients in the HC group were more satisfied with “time 
spent with doctor” than patients in the MC group, perhaps because in the MC protocol 
as compared to HC, the number of outpatient visits and diagnostic procedures was 
restricted. As a result, women in the MC group may have perceived a loss in terms of 
number of outpatient visits and time spent with doctor. In economics, this phenome-
non is referred to as loss aversion [52]. 
 Adherence to the HC and MC protocols was suboptimal, despite considerable 
efforts to promote and support them. Protocol adherence (i.e. the excess number of 
outpatient visits) was only significantly explained by the “communication” subscale of 
the PSQ III questionnaire, although its parameter value indicates that the actual con-
tribution of “communication” to protocol adherence is quite limited. The course of 
antenatal care takes place through close interaction and shared decision-making be-
tween the gynaecologist and the patient. Many factors influence the adherence to a 
guideline in daily practice. We investigated several patient related factors (i.e. recur-
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rence PE/HELLP, depression, anxiety, posttraumatic stress, health-related utility at 
baseline, the level of satisfaction) and these were not associated with the (excess) 
number of outpatient visits. However, apart from patient-related factors, barriers to 
guideline adherence may be related to the individual health care professional, the 
social context and the economic, administrative and organisational context [53]. For 
example, the implementation of a new guideline might be unsuccessful if there is a 
false idea among medical specialists that patients need constant reassurance and a 
long-standing belief that considering costs is unethical, if colleagues do not apply the 
new guideline, if medical specialists question the scientific arguments of the guidelines 
or do not have faith in a successful process. Furthermore, some participating gynae-
cologists already used to work with prediction models in their clinic and the confidence 
of these doctors in our prediction model might have been influenced by previous expe-
riences with other prediction models. Crow’s holistic model is developed from the 
patient’s perspective and does not include health care provider’s and organisational 
characteristics, so it will only partly explain adherence. In our study, we did not meas-
ure these additional factors. An adequate analysis of these potential barriers is an 
important step in improving guideline adherence and, subsequently, quality of care. 
Strengths and limitations 
Our study findings are strengthened by the study design, a multicentre study, which 
contributes to the generalisability of the results. Valid and reliable instruments for 
assessing patient satisfaction and clinical outcomes were used, data were collected 
prospectively with baseline measurements of health state, expectancies and previous 
experiences. Furthermore, factors included in the regression analyses were based on a 
published holistic model of patient satisfaction. 
 A limitation of the study is that we could not compare satisfaction between the 
CAU and the RGC group because we did not measure satisfaction in the CAU group. 
The reason for this is that the larger part of the CAU data were obtained from a histori-
cal cohort of patients. If RGC leads to a reduction in costs compared to CAU, we cannot 
conclude that RGC patients are also more satisfied than CAU patients. However, in this 
non-comparative study, RGC patients appeared overall satisfied with the care they 
received and this is an important indicator of patient acceptability when implementing 
RGC in clinical practice. Second, the finding that only few factors were associated with 
the patient satisfaction subscales and protocol adherence may partly be caused by the 
relatively small sample size. A larger sample size could possibly lead to a statistically 
significant relationship by smaller confidence intervals, leading to potential rejection of 
the null hypothesis (i.e. that there is no relationship). Finally, although extensive clini-
cal and sociodemographic data were collected, there are other patient-related factors 
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(such as values, beliefs and personality) which were not assessed in this study but that 
could affect satisfaction. 
Conclusions 
This study shows that patient satisfaction scores were high in terms of “general satis-
faction”, ”technical quality”, ”interpersonal aspects”, “communication”, “time spent 
with doctor” and “access, convenience and availability”. Overall, HC/MC, psychological 
health state at baseline, expectations and baseline patient satisfaction scores had a 
significant impact on patient satisfaction scores 10 days postpartum. Only the subscale 
“communication” had a significant impact on protocol adherence. 
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Abstract 
Background 
Women who suffered from pregnancy complications are at increased risk for anxiety 
and depression. 
Objective 
To evaluate whether having suffered from preeclampsia or HELLP syndrome is associ-
ated with anxiety and depression, and whether preeclampsia/HELLP is an independent 
risk factor for developing anxiety and depression. 
Search strategy 
Systematic search on PubMed and PsycInfo with no time limit. 
Selection criteria 
Studies presenting original data, including women with a history of preeclamp-
sia/HELLP and at least one comparison group of women without preeclampsia/HELLP, 
reporting the results for each group separately or in a multivariate regression analysis 
with preeclampsia/HELLP as an independent variable. 
Data collection and analysis 
Study characteristics and outcomes were extracted using a prespecified form. If neces-
sary, additional calculations were performed. 
Results 
The search yielded 267 articles, with only six being suitable for inclusion in this review. 
Studies on depression (6) showed generally positive associations between preeclamp-
sia/HELLP and the prevalence of depression or severity of depressive symptoms. How-
ever, the results of three studies were not statistically significant. Studies addressing 
anxiety (2) did not show significant associations between preeclampsia/HELLP and 
anxiety scores. Associations between posttraumatic stress and preeclampsia/HELLP, 
investigated in four studies, were often non-significant. Due to heterogeneity of study 
methods, a meta-analysis of the results was not possible. In most studies, confounder 
control was poor. 
Conclusions 
Evidence is mixed but generally points to positive associations between various forms 
of psychopathology and previous preeclampsia/HELLP. Causality of the associations 
can, however, not be judged adequately. 
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Introduction 
Traditionally, pregnancy is considered a period of well-being and happiness, and was 
once thought to protect women from anxiety and depression (1, 2). However, 20% of 
women experience moderate depression during pregnancy and almost 13% suffer 
from major depressive disorder during the first year postpartum (3, 4). Elevated anxie-
ty levels are found in one out of seven women 30 weeks postpartum (5). Women who 
suffered from pregnancy complications are at higher risk for anxiety and depression (6-
8). During pregnancy and the perinatal period, women are more likely to be exposed to 
stressful situations, such as maternal complications, preterm delivery, fetal distress, 
emergency cesarean section, and maternal or neonatal admission to intensive care. 
 Preeclampsia (PE) and the hemolysis, elevated liver enzymes, and low platelets 
(HELLP) syndrome are common pregnancy complications, together affecting about 3% 
of all pregnancies. To date, it is unknown whether and to what extent these complica-
tions predispose to anxiety and depression. A better understanding of the occurrence 
and severity of anxiety and depression in former PE or HELLP patients may lead to 
improved preventive strategies and targeted interventions. Prevention and timely 
recognition of these anxiety and depression can reduce treatment duration and costs 
(9). Untreated anxiety and depression can persist for years and can adversely affect 
infants (10-13). Currently, the identification and management of anxiety and depres-
sion during pregnancy and the perinatal period are still limited (14). Some studies 
addressing anxiety and depression in women with (a history of) PE or HELLP reported 
increased rates of depression, anxiety, or posttraumatic stress disorder (PTSD) during 
the first months postpartum (15, 16). Other studies, however, failed to substantiate 
these findings (17). Differences in study outcomes may be contributable to differences 
in the designs of these studies and the composition and sizes of the populations en-
rolled. 
 In this article we reviewed the existing literature with respect to two questions. 
The first question was whether former PE/HELLP patients are more likely to have anxi-
ety and depression or more severe anxiety and depression, as compared to women 
without a history of PE/HELLP. The second question was whether PE/HELLP is an inde-
pendent risk factor for developing anxiety and depression. If anxiety and depression do 
occur more often in former PE/HELLP women than in their non-PE/HELLP counterparts, 
differences with respect to other determinants of anxiety and depression may be part 
of the explanation. For this purpose we used the term “anxiety and depression” to 
refer to depressive symptoms, diagnosis of depression, anxiety symptoms, diagnosis of 
anxiety, posttraumatic stress symptoms and posttraumatic stress disorder. Posttrau-
matic stress disorder is a specific form of anxiety that can be triggered by experiencing 
a traumatic, life-threatening event. 
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Material and methods 
Study design/Search strategy 
We systematically reviewed original articles reporting on the occurrence or severity of 
anxiety and depression in women who experienced PE or HELLP as well as women who 
did not experience PE or HELLP during their pregnancy. The study was completed in 
line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines (18). A literature search was conducted in PubMed and PsycInfo in 
March 2013 in order to identify eligible articles. The search was performed with no 
time limit applied to any database. Aiming for a sensitive search strategy, we extended 
the literature search beyond preeclampsia and the HELLP syndrome and also used 
toxemia, pregnancy-induced hypertension, hypertensive disorders of pregnancy and 
hypertensive disorders in pregnancy as search terms. 
 We searched for combinations of search terms in title or abstract by using the 
following free text words: exposure: ‘preeclamp*’ OR ‘pre-eclamp*’ OR ‘pregnancy-
induced hypertension’ OR ‘pregnancy induced hypertension’ OR ‘hypertensive disor-
ders of pregnancy’ OR ‘hypertensive disorders in pregnancy’ OR ‘toxaemia’ OR ‘toxe-
mia’ OR ‘hellp’ OR ‘hemolysis elevated liver enzymes and low platelets’ and outcomes: 
‘depress*’ OR ‘anxiet*’ OR ‘posttraum*’ OR ‘post-traum*’ OR ‘panic’ OR ‘PTSD’ OR 
‘GAD’. 
 The search was limited to studies published in English and included an abstract. 
The search resulted in a total of 267 articles. The following criteria were used to de-
termine whether a study was relevant for the review: 1) the study had to present orig-
inal data; 2) the study had to consider postpartum depression, anxiety, or posttrau-
matic stress as an outcome; 3) the study had to include both women with a history of 
PE/HELLP and a comparison group of women who had not experienced PE or HELLP; 4) 
the study had to either present the results for each group separately, or present the 
results of a multivariate regression analysis in which the diagnosis of PE/HELLP was 
considered as an independent factor, or both. 
 Retrieved records were collected in alphabetical order. Duplicates were removed 
and non-relevant titles were excluded. The main reason for excluding articles was that 
these studies involved topics or subjects that were not related to the purpose of this 
review. Abstracts were obtained of all potentially eligible articles that remained after 
the title screening. Two reviewers (D.D. and C.D.) independently assessed the rele-
vance of the remaining abstracts. Any discrepancies regarding inclusion or exclusion of 
a study were resolved by reading the full article and discussion. Both reviewers exclud-
ed 14 abstracts. One reviewer (D.D.) read all remaining articles in full, while a second 
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reviewer was consulted (C.D.). We also conducted a hand search of the reference list 
of the eligible articles to identify additional studies. 
Data extraction and quality aspects 
Data extraction was performed by one of the authors (D.D.). Extracted data were 
checked for completeness and correctness by the second author (C.D.). Any disagree-
ments were resolved by either discussion or by consulting a third reviewer (L.S.). For 
each paper, the reviewers extracted basic study characteristics with respect to author-
ship, year of publication, research question/aim, study design (such as type of study, 
inclusion moment), study population (such as patient characteristics, sample size), 
outcome(s) of interest, data collection method and instruments. Moreover, the find-
ings of interest for the current review were extracted. 
 A short critical appraisal checklist was used in order to facilitate data extraction 
and evaluate the appropriateness of the studies in light of our review questions. This 
evaluation was not used to assign weights or exclusion criteria, but rather as a subject 
for discussion. The checklist was adapted from the Newcastle-Ottawa Quality Assess-
ment Scale for cohort studies (19). This scale has established content validity and inter-
rater reliability (19). The individual components of the checklist were rated according 
to a Y/N/? system rather than according to the allocation of stars per rating sheet. 
With the checklist we assessed whether the non exposed cohort was drawn from the 
same community as the exposed cohort, whether the exposure was ascertained by a 
physician, how the outcome was assessed (such as medical records, self-report), 
whether a non-response analysis was performed, whether the recall period was longer 
than implicated in the questionnaires and whether the same follow-up period was 
applied for all patients. 
Confounder control 
For the purpose of the second review question (i.e. whether PE/HELLP is an independ-
ent risk factor for developing anxiety and depression), confounder control and han-
dling of intermediate variables were specifically considered important. Treating inter-
mediates as confounders is not appropriate as it may introduce, rather than control 
for, bias in the association between PE/HELLP and anxiety and depression. Further 
elaboration on handling of potential confounders and intermediate factors can be 
found elsewhere (20). 
 Based on the literature, we considered the following factors potentially important 
confounders in the association between PE/HELLP and anxiety and depression: mater-
nal obesity (21-23) , low socioeconomic status (24-27), previous mental illness (28-30), 
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pre-existing medical conditions (27, 31, 32), age (27, 33, 34), parity (35-37) and non-
Western ethnicity (38-40). These factors are risk factors of anxiety and depression and 
are related to PE/HELLP. Ideally, these factors should be treated as potential con-
founders in each study. Other risk factors for anxiety and depression may be on the 
causal path between PE/HELLP and anxiety and depression and should therefore not 
be treated as confounders. These factors include mode of delivery, gestational age, 
birthweight, suspicion of fetal distress, Apgar score, perinatal death, hospital admis-
sion of mother or child and anxiety and depression during pregnancy. 
Results 
Figure 1 summarizes the literature identification and selection procedure. Of the 267 
articles identified in the PubMed/PsycInfo search, six articles ultimately met the inclu-
sion criteria, i.e. Engelhard et al., 2002 (16); Brussé et al., 2008 (17); Baecke et al., 2009 
(41); Blom et al., 2010 (15); Gaugler-Senden et al., 2011 (42); Stramrood et al., 2011 
(43). The reference check did not reveal any additional relevant articles. 
 
Table 1 lists the main characteristics of all studies included in the systematic review. 
The selected articles comprised four retrospective cohort studies and two prospective 
cohort studies. All studies were performed in the Netherlands. Sample sizes ranged 
from 20 to 4941, with a total of 5636 women included. One author participated in two 
different studies but inclusion of patients in these studies took place in different time 
periods (16, 41). One author participated in three different studies and we could not 
rule out a possible overlap of patients between these studies because inclusion of 
patients in these studies took place in the same period and in the same hospital (15, 
17, 42). Therefore, we contacted this author who assured us that there was no such 
overlap. Two studies included two groups, of which one included severe PE patients 
and women with uncomplicated normotensive pregnancies (17), and the other includ-
ed severe, early-onset PE/HELLP patients with preterm delivery and healthy partici-
pants with a preterm delivery (42). One study included three groups, PE patients, pa-
tients with preterm premature rupture of membranes and women with uncomplicated 
pregnancies (43). Two studies each included four groups, patients with preterm PE, 
patients with term PE, patients with preterm birth and patients with an uneventful 
pregnancy (15, 16, 41). Blom et al. (15) included a general sample of pregnant women 
and examined a wide range of perinatal complications (among which was PE) as poten-
tial risk factors for postpartum depression. All selected studies reported on depression, 
four studies reported on PTSD (16, 41-43) and two studies reported on anxiety (17, 
41). 
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Figure 1: Study selection process 
Search of electronic databases: Pubmed, PsycInfo
Identification of articles:
PubMed = 230, PsycInfo = 37: total = 267
Duplicates removed (n=20)
Rejection of 215 articles on the basis of title 
screening:
irrelevant subject/topic (167), review, 
tutorial, case-description (40), depression/
anxiety as predictors/risk factors, not 
outcome (7), other population (1)
Screening of 32 abstracts
Rejection of 18 articles on the basis of 
abstract screening:
depression/anxiety as predictors/risk 
factors, not outcome (8), results not 
specified/presented per comparative group 
(3), review, tutorial, case-description (3), 
non-comparative study (2), irrelevant topic 
(2)
Full texts obtained for:
PubMed = 13, PsycInfo = 1: total = 14 full texts
Data extraction form 
Rejection of 8 articles:
depression/anxiety as predictors/risk 
factors, not outcome (3), results not 
specified/presented per comparative group 
(3), non-comparative study (2)
Inclusion of 6 articles in the review
Screening of 247 titles
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Quality aspects 
Index cases and control women were recruited from the same source population in all 
studies but one. Stramrood et al. (43) recruited pregnant women with PE or HELLP in 
the hospital, whereas healthy controls with uneventful pregnancies were recruited in 
an independent midwifery practice. All the other studies recruited both PE or HELLP 
patients and comparison group(s) from the same source, i.e. the hospital. 
 In all studies, exposure (PE/HELLP) was ascertained by a physician. Outcome as-
sessment was done using validated questionnaires in all studies. Recall periods were 
no longer than implicated in the questionnaires used in all studies but one. In the study 
of Gaugler-Senden et al. (42) the recall period varied from four up to 12 years. Timing 
of assessment was equal for all patients in only two studies (15, 43). 
 Blom et al. (15) performed a non-response analysis showing that women with 
missing data reported more psychopathological symptoms, poorer family functioning, 
had a lower family income, were less educated, were more likely to be of non-Western 
origin and younger than responders. Engelhard et al. (16) and Gaugler-Senden et al. 
(42) reported response rates of the different groups and showed no significant differ-
ences between respondents and non-respondents with regard to age, parity, gesta-
tional age at delivery, prolongation of pregnancy or year of delivery. Baecke et al. (41) 
reported response rates of the different groups, but did not analyze differences between 
responders and non-responders. Brussé et al. (17) did neither report response rates, nor 
investigate differences between responders and non-responders. Stramrood et al. (43) 
included 193 women, whereas at the end of the study, only 137 participants were left. 
There may be selective drop-out since women who did not take part at the end of the 
study had a slightly lower educational level and were younger than participants. 
Reported outcomes of the selected studies 
The most frequently studied outcome was depression, followed by posttraumatic 
stress and anxiety. Concerning these outcomes, a distinction was made between oc-
currence and severity. Four studies used cut-off points for the questionnaires to meas-
ure clinical levels of the outcomes, i.e. diagnoses (15, 16, 41, 43). 
Review question 1 
The following sections address the first review question, i.e. whether anxiety and de-
pression occur more frequently or are more severe after PE/HELLP than after a preg-
nancy not complicated by PE/HELLP. Table 2 summarizes the results of the studies. For 
the purpose of the first review question, it is important that a study allows a separate 
comparison of women with PE/HELLP to women without PE/HELLP. 
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Depression 
Three studies used the Beck Depression Inventory (BDI) (16, 41, 43), one study used 
the Zung Depression Scale (42), one study used the Edinburgh Postnatal Depression 
Scale (EPDS) (15) and one study used the Center for Epidemiological Studies Depres-
sion Scale (CES-D) (17) for the measurement of depression. Three studies measured 
severity (17, 41, 42) and three studies measured occurrence (15, 16, 43). Most of the 
studies showed positive associations between PE/HELLP and the prevalence of depres-
sion and severity of depressive symptoms. All studies but one reported no significant 
differences in occurrence or severity of depression among the groups (16, 17, 41-43). 
Only three studies reported results in such a way that review question 1 could be an-
swered directly (15, 17, 42), of which one measured prevalence (15) and two severity 
(17, 42). The studies including three or more groups did not separately compare wom-
en with PE/HELLP to women without PE/HELLP and are therefore not directly useful to 
answer our first review question (16, 41, 43). However, we performed calculations 
ourselves in order to answer review question 1 with these studies. Using the data re-
ported in the study of Engelhard et al. (16), we found a significant difference in the 
occurrence of depression between term PE and term patients without PE, and we 
found no significant difference between preterm PE patients and patients delivering 
preterm without PE. The study of Brussé et al. (17) reported no significant differences 
in the severity of depression between PE patients and normotensive healthy controls. 
With the study of Baecke et al. (41), we found a significant difference in the severity of 
depression between preterm PE and healthy preterm patients and no significant dif-
ference between term PE and healthy term women. The study of Blom et al. (15) re-
ported that PE was significantly associated with an increased risk of postpartum de-
pression. The study of Gaugler-Senden et al. (42) reported no significant differences in 
the severity of depression between preterm PE/HELLP and healthy preterm patients, 
neither current, nor recalled directly postpartum. Using the data of Stramrood et al. 
(43), we found no significant differences in the occurrence of depression between 
PE/HELLP and healthy pregnant women, neither six weeks postpartum, nor 15 months 
postpartum. 
Anxiety symptoms 
Two studies used the State-Trate Anxiety Inventory (STAI) for the measurement of 
anxiety symptoms (17, 41) and only severity was measured, since the STAI is not a 
diagnostic instrument. Both studies showed higher anxiety severity scores among 
women with PE, however, these differences were not significant. Only one study re-
ported results in such a way that review question 1 could be answered directly. The 
study of Brussé et al. (17) reported no significant differences between PE patients and 
the healthy controls regarding the severity of anxiety symptoms. The study of Baecke 
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et al. (41) included more than three groups but did not separately compare women 
with PE to women without PE. However, we performed calculations ourselves and 
found no significant differences in the severity of anxiety between preterm PE patients 
versus healthy preterm patients and term PE patients versus healthy term patients. 
Posttraumatic stress 
Two studies used the Impact of Event Scale (IES) (41, 42) and two other studies used 
the PTSD Symptom Scale (16, 43) for the measurement of posttraumatic stress. Two 
studies measured severity (41, 42) and three studies measured occurrence (16, 41, 43). 
In general, women with PE/HELLP have higher prevalence and severity rates of post-
traumatic stress than their counterparts. 
 All studies showed significantly different levels or a significantly different preva-
lence of posttraumatic stress among the groups (16, 41-43), but only two reported 
results in such a way that review question 1 could be answered directly (41, 42). Again, 
we performed calculations ourselves in order to answer the first review question. With 
the study of Engelhard et al. (16), we found a significant difference in the occurrence 
of PTSD between term PE and healthy term patients and no significant difference be-
tween preterm PE and healthy preterm patients. With the study of Baecke et al. (41), 
we found no significant differences in the severity and occurrence of posttraumatic 
stress between preterm PE versus healthy preterm patients and term PE versus 
healthy term patients. The study of Gaugler-Senden et al. (42) reported no significant 
differences as recalled directly postpartum in the severity of posttraumatic stress be-
tween preterm PE/HELLP and healthy preterm patients. However, it reported signifi-
cant differences in current severity of posttraumatic stress between the two groups. 
 Reanalyzing the data of the study of Stramrood et al. (43), we found no significant 
difference in the occurrence of PTSD at six weeks postpartum between PE/HELLP pa-
tients and women with an uncomplicated pregnancy. However, there was a significant 
difference in the occurrence of PTSD at 15 months postpartum between the two 
groups. 
Review question 2 
Table 3 describes different strategies applied in the studies to control for confounding. 
The strategies for confounder control differed between studies as did the selection of 
confounders. Restriction was applied in five of the six studies. Three studies unfortu-
nately restricted for potential intermediates such as fetal death (16, 17, 43). Two stud-
ies conducted matching (17, 43), however, matching categories within variables were 
not made explicit in both studies, and potential intermediates such as mode of delivery 
(17) and gestational age (42) were among the matching factors. Three studies con-
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trolled for possible covariates in a multivariate analysis (15, 16, 43). However, all stud-
ies adjusted for potential confounders as well as potential intermediate factors. None 
of the studies controlled for maternal BMI, and only two controlled for previous men-
tal illness (17, 43). 
 The second review question, i.e. whether previous PE/HELLP is an independent 
risk factor of subsequent anxiety and depression, was considered to be answered if a 
study controlled for at least four possible confounders (as defined previously) and 
ideally, did not control for intermediates. Since controlling for intermediate factors and 
insufficient control for confounders can bias associations towards the null as well as 
away from it, Blom et al. (15) provides the most valid evidence with respect to our 
second review question. The study of Engelhard et al. (16) controlled for only two 
previously defined confounders and for too many intermediates; Brussé et al. (17) 
controlled for only three previously defined confounders, but fortunately, did control 
for only a few intermediates; Baecke et al. (41) controlled for no previously defined 
confounders; Gaugler-Senden et al. (42) controlled for three previously defined con-
founders, and controlled for one intermediate. Brussé et al. (17) excluded patients 
when a reliable assessment of cognitive functions could not be made due to severe 
psychiatric symptoms. However, they did not define severe psychiatric symptoms and 
therefore, it is unclear whether they were present before the development of PE. Blom 
et al. (15) adjusted for general psychopathological symptoms as a covariate, however, 
they just stated that general psychopathological symptoms included at least depres-
sion and anxiety. Again, it is unclear whether they were present before the develop-
ment of PE. Treating severe psychiatric symptoms and general psychological symptoms 
(15) and severe psychiatric symptoms (17) as confounders is only appropriate in case 
they were present before the development of PE, which was not reported. Therefore, 
‘severe psychiatric symptoms’ and ‘general psychological symptoms’ are described as 
‘other factors’ instead of confounders in Table 3. 
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Discussion 
We have summarized the available evidence about the incidence and occurrence of 
anxiety and depression in patients who experienced a pregnancy complicated by PE or 
HELLP and put the evidence in a methodological context. We identified six cohort stud-
ies (four historical and two prospective) examining occurrence or severity of anxiety 
and depression in women who developed PE or HELLP syndrome during pregnancy 
compared to women who did not experience any of these pregnancy complications. 
 Our first review question was whether former PE/HELLP patients are more likely 
to have anxiety and depression or more severe anxiety and depression, compared to 
women without a history of PE/HELLP. With respect to depression, the evidence is 
mixed. Although nearly all studies showed positive associations between PE/HELLP and 
prevalence of depression or severity of depressive symptoms, the results of three of 
them were not statistically significant (17, 42, 43). Of the two studies distinguishing 
between term and preterm deliveries, one showed an increased prevalence among 
women with PE and term births (depression prevalence 26% versus 7% of healthy term 
women; PTSD prevalence 17% versus 0% of healthy term women) (16), whereas the 
other showed increased severity among women with PE and preterm deliveries (de-
pression severity of 2.7 vs. 1.2 of healthy preterm women; anxiety severity 39.9 vs. 
35.4 of healthy preterm women; PTSD prevalence 44% vs. 41% of healthy preterm 
women; PTSD severity 25.3 vs. 20.0 of healthy preterm women) (41). The two studies 
addressing anxiety showed no significant associations between PE and anxiety scores, 
although differences were in the expected direction, i.e. higher scores among women 
with PE (17, 41). In the four studies addressing posttraumatic stress, associations were 
generally in the expected direction, i.e. higher prevalence and severity among women 
with PE/HELLP, and three of them were partly significant (16, 42, 43). The results of 
two studies indicate that the posttraumatic stress symptoms may increase over time 
(42, 43). 
 Our second review question was whether PE/HELLP is an independent risk factor 
of anxiety and depression. In most studies confounder control was poor. Some studies 
treated potential intermediate factors as confounders, which may lead to underesti-
mation of effects. One study, addressing the occurrence of depression, controlled for a 
number of potential confounders and intermediate factors and still found a statistically 
significant association with PE. This indicates that PE/HELLP may be an independent 
risk factor of subsequent depression (15). 
 It can be argued that non-significant results are not a problem since it can be 
solved by pooling the data. However, we could not perform a meta-analysis because 
comparability of studies was poor due to different subgroups, different outcomes 
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(occurrence and severity), different questionnaires, different cut off points and differ-
ent follow-up lengths. 
 Although in all studies validated questionnaires for outcome assessment were 
used, only in two were they submitted to patients at fixed time points after the preg-
nancy affected by PE or HELLP. As prevalence and severity of anxiety and depression 
may increase or decrease as a function of time after delivery, interpretation of the 
results of studies not using fixed assessment points is complicated. Studies used differ-
ent questionnaires to screen for anxiety and depression with different validity and 
reliability (4, 44). Although PSE/SCAN or SCID interviews would be the gold standard 
for measurements in psychopathology, they are very time-consuming and therefore 
not appropriate in clinical studies in which many patients are included. It has been 
found that self-report measures are fairly accurate in assessing emotions and behav-
iors. Within the research context, if large-scale screening does occur, it is more time-
efficient to conduct clinical interviews with only those patients scoring above the cut-
off score (44). Only three instruments (Bromley Postnatal Depression Scale, Edinburgh 
Postnatal Depression Scale, Postpartum Depression Screening Scale) have been devel-
oped specifically to measure postpartum depression, whereas other instruments 
measure general symptoms of depression. Reviews of screening instruments for post-
partum depression found that the EPDS, the BDI-II and the PDSS have greater sensitivi-
ty and specificity in the perinatal population than other measures that have been test-
ed (45). There is no literature concerning the optimal choice of measurement instru-
ments for anxiety and posttraumatic stress in perinatal settings. 
 Furthermore, one study asked participants to recall their mental health status 
over a longer period than implicated in the questionnaire (up to 12 years), which is 
likely to have led to considerable misclassification (42). 
 All included studies were performed in the Netherlands among predominantly 
Caucasian women. Results may therefore not be applicable to non-Caucasian women. 
Although most studies mentioned the number of women unwilling to participate in the 
study (response rates ranging from 48- 90%), most did not present data comparing 
characteristics of respondents and non-respondents. Therefore it is not possible to 
evaluate representativeness of the study population. Study participation may be asso-
ciated with mental health. 
 Depression and anxiety disorders have been identified as risk factors of PE (29, 
46). Furthermore, the risk of postpartum depression is strongly associated with pre-
pregnancy psychopathology (47). Therefore, controlling for pre-pregnancy mental 
health is essential in unraveling the causal relation between PE and psychopathology. 
Most of the studies included in this review did not obtain measures of maternal mental 
health status before the diagnosis of PE or HELLP was made (15, 16, 41-43). Blom et al. 
(15) adjusted for general psychopathological symptoms as a covariate, but mentioned 
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that these symptoms were measured at 30 weeks of gestation which may be after the 
diagnosis of PE. Stramrood et al. (43) measured depression and BDI scores after the 
diagnosis of PE or HELLP was made; thus, part of the psychopathology might have 
been caused by the pregnancy complication and controlling for it may be unjustified. 
Conclusions and implications for further research 
Evidence about the association of PE/HELLP with subsequent psychopathology is 
mixed. Differences between study methodologies are likely to have contributed to the 
heterogeneity of the results. Nevertheless, associations that were found were general-
ly in the same direction, i.e. towards higher prevalence/severity of psychopathology in 
women with previous PE/HELLP, in comparison to women with no such history. In 
order to be able to better evaluate causality of the associations, evidence is needed 
from studies controlling for important potential confounders including psychopatholo-
gy at baseline. Such studies should preferably be prospective and have outcome meas-
urements at fixed time points. 
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Summary and General discussion 
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The studies presented in this thesis were centered around comparing the psychological 
and economic effects of obstetrical care-as-usual (CAU) with obstetrical care based on 
a risk-guided guideline (RGC) in women with a history of PE/HELLP in the Netherlands. 
The latter form of care was integrated with a newly developed prediction rule for es-
timation of recurrence risk of PE/HELLP. Although earlier studies on single predictors 
for recurrent PE/HELLP consistently reported their limited sensitivity, multi-parameter 
tools for the prediction of recurrent PE/HELLP have only recently become available (1). 
Clinical guideline 06 of the Dutch Society of Obstetrics and Gynecology (NVOG) only 
focuses on hypertensive disorders in pregnancy developing for the first time (2), 
providing recommendations for the use of antihypertensive drugs, corticosteroids, the 
prophylactic use of magnesium sulphate, and how to counsel the mother about the 
prognosis of her unborn child. However, to the best of our knowledge, there is no such 
guideline for prenatal care of women with a history of PE/HELLP, even though preg-
nant women with a history of PE/HELLP are at increased risk of recurrent PE/HELLP and 
other placental syndromes. This lack of a standardized management directive was the 
most important motive to set up the PreCare study. In addition to reporting on the 
PreCare study, we critically reviewed the literature about mental health problems 
among women with a history of PE/HELLP. 
Main findings 
In this thesis, the following topics are presented in consecutive order: study design of 
the PreCare study (Chapter 2), description of CAU (Chapter 3), cost-effectiveness anal-
ysis of RGC versus CAU (Chapter 4), patient satisfaction with RGC (Chapter 5), system-
atic review on anxiety and depression after PE/HELLP (Chapter 6). 
 
Chapter 2 elaborates on the study protocol. The PreCare study uses a before-after 
design, in which pregnancy outcome and costs are compared between CAU and RGC. 
In CAU, gynecologists did not receive any instructions and were requested to manage 
their patients in whatever manner they deemed appropriate. RGC consisted of two 
levels of care intensity, with Medium Care (MC) including 9 to 11 outpatient visits, and 
High Care (HC) including 14 to 16 outpatient visits plus optional additional diagnostics. 
For a cost-effectiveness analysis with a time horizon of one year (start pregnancy-3 
months postpartum), we calculated two incremental cost-effectiveness ratios (ICERs) 
expressing 1) the cost per Quality Adjusted Life Year, i.e. QALY (mother unit of analy-
sis), performed from the societal perspective, and 2) the cost per prevented neonatal 
adverse outcome, i.e. NICU admission and/or death (child unit of analysis), performed 
from the hospital perspective. 
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Chapter 3 describes hospital resource usage in terms of diagnostic tests, outpatient 
visits, admissions, deliveries and pregnancy-related costs in a historical cohort of preg-
nant women who had a previous preeclamptic pregnancy and who were treated ac-
cording to CAU. The chapter also evaluates how this resource usage is related to preg-
nancy outcome. We focused our analysis on the outcome and costs from the start of 
pregnancy until delivery, as hospital care required by the newborn is excluded from 
obstetrical CAU provided by gynecologists/obstetricians. Maternal hospital costs per 
patient averaged €8,047, with main cost drivers being maternal admissions and ma-
ternal outpatient visits, which together comprised over 80% of the total hospital costs. 
Costs are particularly high in conjunction with preterm birth and/or recurrent 
PE/HELLP. The content of CAU for pregnant women with a history of PE/HELLP varied 
considerably, with the number of outpatient visits ranging from 5 to as many as 37. 
Although multiple regression analyses indicated that some pregnancy outcomes im-
pacted maternal hospital costs, most of the variation in maternal hospital costs re-
mained unexplained. Although variables not measured in this study (e.g. patient pref-
erences, doctor practice style, local hospital policy) may explain some of this variation, 
most of it is likely to remain unexplainable. The latter supports the view that clinical 
management of this particular patient population may be improved by e.g. developing 
an evidence-based guideline. 
 In Chapter 4, RGC was compared with CAU with respect to costs, effects and cost-
effectiveness. The study used a before-after design. Two incremental ICERs were calcu-
lated expressing 1) the cost per QALY (mother unit of analysis), from the societal per-
spective, and 2) the cost per prevented adverse neonatal outcome, i.e. NICU admission 
and/or death (child unit of analysis), from the hospital perspective. The base-case 
results of the cost per QALY analysis show that RGC was not cost-effective compared 
to CAU from a societal perspective due to both lower QALYs and higher costs in the 
RGC group. Bootstrap results showed that effectiveness was also consistently lower in 
the RGC group (99% of replications) with societal costs being higher for RGC for almost 
80% of the replications. From the hospital perspective, the cost per prevented adverse 
outcome analysis indicated RGC to be more cost-effective than CAU, mainly due to 
lower hospital costs. In most cases, sensitivity and subgroup analyses for both perspec-
tives confirmed the results of the base-case analyses. 
 In Chapter 5, we explored whether patients in the RGC group were satisfied about 
the care received, about the factors contributing to patients’ level of satisfaction and 
whether level of satisfaction influenced protocol adherence. Patient satisfaction scores 
were high for each subscale of the PSQ III. Differences between HC and MC patients 
were small and inconsistent. However, after correction for potential confounders, HC 
patients were more satisfied than MC patients about “time spent with the doctor”. 
Patients’ expectations/previous experiences, baseline psychological health status and 
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being assigned to either HC or MC had a significant impact on satisfaction. Only satis-
faction with “communication” appeared to be a predictor of adherence score. 
 Chapter 6 presented a systematic review evaluating whether having experienced 
PE/HELLP predisposed to anxiety and depression. A better insight into the develop-
ment and severity of mental health problems in former PE/HELLP patients may help to 
develop more effective prevention and management strategies. A literature search 
was conducted in PubMed and PsycInfo with no limit regarding date of publication, but 
limited to studies reported in English and containing an abstract. The search yielded 
267 articles, with only six suitable for inclusion in this review. A critical appraisal check-
list was used to facilitate data extraction and to evaluate the studies’ appropriateness 
with respect to our research questions. Studies on post PE/HELLP depression (n=6) 
showed generally positive associations between PE/HELLP and the prevalence of de-
pression or severity of depressive symptoms, but the associations were statistically 
insignificant in half of the studies. Studies addressing anxiety (n=2) showed increased 
severity scores after PE/HELLP, but all evaluated associations were statistically insignif-
icant. Studies on posttraumatic stress showed in general a higher prevalence and high-
er severity scores of posttraumatic stress, but again, these findings were often statisti-
cally insignificant. Thus, even though the reported associations did not reach statistical 
significance, the direction of almost all these associations was positive. The latter pro-
vides some indirect support for the view that a history of PE/HELLP may predispose to 
the subsequent development of various forms of psychopathology. 
Reflection on the results 
The results of the PreCare study support the concept that -irrespective of pregnancy 
outcome- standardization of care for pregnant women with a history of early-onset 
PE/HELLP may reduce the huge variation in maternal hospital costs (Chapter 3). It may 
also be more cost-effective than CAU from a hospital perspective (Chapter 4). On the 
other hand, from a societal perspective, CAU is preferred over RGC, which is reflected 
in higher QALYs and less maternal health care costs outside the hospital in the CAU 
group. Especially women assigned to MC reported lower QALYs and higher health care-
related expenses outside the hospital. Interestingly, MC patients were also significantly 
less satisfied with “time spent with doctor” compared to HC patients (Chapter 5). Our 
systematic review on the available evidence about the severity and occurrence of anx-
iety and depression in patients who experienced a pregnancy complicated by PE/HELLP 
suggested that these women may be prone to more postpartum anxiety and depres-
sion, although the evidence for such a predisposition awaits confirmation in a suffi-
ciently powered prospective study (Chapter 6). 
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All women included in the PreCare study had a previous pregnancy complicated by 
early-onset PE/HELLP. Therefore, these women can be expected to be more anxious 
than their counterparts with a preceding uneventful first pregnancy. It is possible that 
these women systematically interpret ambiguous information in the informed consent 
document as more threatening than women with a history of uneventful pregnancies 
only (3). A restriction in the number of outpatient visits in the MC protocol (relative to 
HC and CAU) may be experienced as threatening. Furthermore, MC women may have 
perceived a loss in optimal care provision in conjunction with the restriction in number 
of anticipated outpatient visits. This phenomenon is referred to as “loss aversion”, 
where losses have greater subjective weight than equivalent gains (4). As a result, MC 
patients may report on average lower patient satisfaction scores with “time spent with 
doctor”, higher costs outside the hospital and lower QALYs. These issues may explain 
the lower cost-effectiveness in RGC relative to CAU (societal perspective). 
Methodological considerations 
In interpreting the results of this thesis, it is relevant to consider the methodology used 
to obtain the data. Here, we want to elaborate on the validity of the prediction model, 
the use of a before-after design, the size of the group for the prospective CAU study, 
the absence of a comparison group in the study on satisfaction with RGC and protocol 
adherence, topics which have not been addressed in detail in previous chapters. 
Prediction model 
For the purpose of this study, we developed a prediction model, which would allow us 
to differentiate between former patients who are and are not at high risk to develop 
recurrent PE in their next pregnancy (5). This approach would allow us to offer RGC to 
former patients and enable us to determine, whether this more or less customized 
care would be superior over CAU regarding cost-effectiveness, patient satisfaction and 
pregnancy outcome. Unfortunately, this prediction model discriminated poorly be-
tween low-risk and high-risk former patients and therefore, in its present form, was 
unsuitable for introduction in clinical practice to serve as an adequate basis for RGC. 
Before-after design 
Although the preferred design for evaluating the implementation of a new care strate-
gy would be a randomized controlled trial (RCT), we chose a before-after design for 
several reasons. In the case of PreCare, an RCT would mean that CAU or RGC would be 
offered at random either at patient level or at hospital level. A study randomized on a 
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patient level would have been vulnerable to contamination, implying that gynecol-
ogists would be able to apply the same knowledge about the risk of recurrence of 
patients assigned to the CAU group as of patients assigned to the RGC group, and pos-
sibly use this knowledge as a guide for the intensity of antenatal care, thereby dimin-
ishing any possible effects between CAU and RGC (6). A study randomized on hospital 
level would have been sensitive to local protocols on care in the hospitals assigned to 
the CAU group, or the adherence to protocols offered to hospitals assigned to the RGC 
group. Therefore, a before-after study design was chosen in which at least all hospitals 
that participated in the before part, would also participate in the part after implemen-
tation of the prediction rule. This approach circumvents the problem of bias intro-
duced by large differences between hospitals. 
Small group for prospective CAU 
In the CAU group, patients were followed both prospectively and retrospectively. We 
chose to identify most CAU patients retrospectively using hospital information systems 
and medical records in order to save time to complete the study. These patients had 
been diagnosed with PE/HELLP between 1996 and 2012 and thus, had received CAU. 
The women in this retrospective CAU group and those in the RGC group were matched 
with one another for age, gestational age of birth in the previous pregnancy and cen-
ter. As a consequence, the number of CAU patients followed prospectively was rela-
tively small. Only prospectively followed patients were able to fill out questionnaires 
regarding costs outside the hospital, health-related quality of life, anxiety, depression 
and posttraumatic stress. The use of smaller groups may come with greater uncertain-
ty as regards cost-effectiveness results; this was however appropriately handled using 
bootstrap analysis. 
Comparison of satisfaction between RGC and CAU was not possible 
In our satisfaction study, we could not compare satisfaction between CAU and RGC as 
we did not measure satisfaction in the CAU group. The reason for this is that the larger 
part of the CAU data were obtained from a historical cohort of patients and these 
patients did not receive patient satisfaction questionnaires (see above). By the time 
the satisfaction questionnaire was in its final form, i.e. the questions which were spe-
cifically formulated for evaluation of PreCare, the prospective CAU patients were al-
ready included. Unfortunately, we were unable to explore whether RGC patients were 
more satisfied than CAU patients. 
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Protocol adherence 
Despite considerable efforts to promote maximum compliance of the participating 
gynecologists with our protocols, adherence to the MC and HC protocols was poor. 
Nowadays, most studies focus on outcome rather than on the process involved in 
implementing an intervention, treatment option or protocol (7). Conventional cost-
effectiveness analyses explore whether a new treatment is cost-effective. However, 
only few studies disentangle the factors that ensure successful outcomes, characterize 
the failure to achieve success, or attempt to document the steps in achieving success-
ful implementation of an intervention, new treatment or protocol (8-11). Process eval-
uations within studies explore the implementation, receipt and setting of a new treat-
ment option and facilitate the interpretation of the outcome results. Such process 
evaluation was not intended in the PreCare study. However, it may provide an im-
portant policy message. 
 Process evaluations examine the views of the participants (doctors, patients) and 
study how the intervention is implemented. Several methods can be used to collect 
process data, for example focus groups, interviews or questionnaire surveys. Particu-
larly in case of an unexpected or disappointed outcome, researchers and funders 
would like to understand why the expected outcome was not achieved. Thus, integrat-
ing process and outcome data can help to interpret unexpected study results. 
Recommendations for future research and clinical practice 
Our prediction model performed poorly in women with a history of early-onset 
PE/HELLP (12). A challenge for future research would be to develop a new prediction 
rule with better discriminatory performance. If such a test becomes available, a logical 
next step would be to explore whether a newly developed RGC is more cost-effective 
than the current CAU. If initial positive study results are confirmed by more than one 
study group in large numbers, recommendations can be included in guidelines and 
provide a new starting point for further research. It is well known that newly devel-
oped prediction models require external validation because of design deficiencies or 
overfitting (13). Ideally, the PreCare study would have been designed with an integrat-
ed process evaluation, taking into account the views of doctors and patients. Addition-
ally, our study provides support for the concept that being informed ahead about pos-
sible barriers and facilitators for implementation is likely to improve protocol adher-
ence (14, 15). 
 RGC differed from CAU by higher expenses outside the hospital, a lower health-
related quality of life and probably a lower patient satisfaction score (especially in the 
subgroup of MC patients). The latter was probably related to a lower allowance for 
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outpatient visits in MC than in HC and this may have urged these patients to consult 
alternative health care providers outside the hospital. Therefore, future protocols 
should also take into account (health) care outside the hospital. For example, it would 
be interesting to offer preventive mental health measures to women with a history of 
early-onset PE/HELLP, thus helping them to cope better with the stress associated with 
a new pregnancy. These patients with a higher risk for anxiety and depression may 
benefit from tailored information via internet or same-day-call-back service by the 
obstetrician or a specialized nurse practitioner. This strategy will not only reduce this 
apparent extra need for regular reassurance. It will also prevent them from consulting 
other health care providers (outside the hospital). Nowadays, gynecologists give priori-
ty to the patient’s clinical condition. However, the systematic review conducted along-
side the PreCare study shows that attention for anxiety and depression should not be 
ignored. Only a small percentage of these women will develop an early-onset recur-
rence. However, all former patients had been exposed to stressful situations in their 
previous pregnancy. Prevention and timely recognition may reduce treatment costs 
(outside the hospital), improve health-related quality of life and patient satisfaction. 
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In hoofdstuk 1 van dit proefschrift worden de zwangerschapsaandoeningen pre-
eclampsie en het HELLP syndroom, het vóórkomen, het herhalingsrisico in een volgen-
de zwangerschap en de mogelijkheid om een herhaling te voorspellen kort geïntrodu-
ceerd. Het hoofdstuk wordt afgesloten met de specifieke doelstellingen en inhoud van 
het proefschrift.  
 Bij preëclampsie is er naast hoge bloeddruk in de zwangerschap ook sprake van 
eiwitverlies in de urine. Het HELLP-syndroom staat voor “Hemolysis, Elevated Liver 
enzymes en Low Platelets”. Dit betekent dat er sprake is van een verhoogde afbraak 
van rode bloedcellen en een gestoorde leverfunctie. Daarnaast is er een tekort aan 
bloedplaatjes, waardoor de bloedstolling ontregeld raakt. Sommige vrouwen hebben 
lange tijd weinig of geen klachten, anderen worden in korte tijd ernstig ziek. Pre-
eclampsie en het HELLP-syndroom kunnen ook ernstige gevolgen hebben voor het 
kind, zoals groeivertraging en vroeggeboorte. Hoewel bekend is dat preëclampsie en 
het HELLP-syndroom ontstaan door onvoldoende werking van de placenta (moeder-
koek), is de exacte oorzaak nog niet duidelijk. Vrouwen die eenmaal preëclampsie of 
het HELLP-syndroom hebben doorgemaakt, hebben een verhoogde kans op herhaling 
in de volgende zwangerschap. Er zijn in Nederland geen klinische praktijk-richtlijnen 
voor de begeleiding van zwangere vrouwen met een dergelijke complicatie in de voor-
geschiedenis. Veelal krijgen deze vrouwen zeer intensieve en kostbare zorg, terwijl dat 
in de meeste gevallen misschien niet nodig is. Vrouwen met een laag herhalingsrisico 
zouden misschien reguliere zorg kunnen krijgen, terwijl voor vrouwen met een hoog 
herhalingsrisico een dergelijke intensieve zorg wel te rechtvaardigen is. Om onder-
scheid te maken tussen vrouwen met een laag herhalingsrisico en vrouwen met een 
hoog herhalingsrisico, werd een predictiemodel ontwikkeld. In de PreCare studie wer-
den de effecten van dit predictiemodel verder onderzocht op het gebied van uitkom-
sten bij moeder en kind, patiënttevredenheid en maatschappelijke en zorgkosten (re-
cidiefkans-geleide zorg, of RGC). Op basis van dit predictiemodel werden vrouwen 
ingedeeld in Medium Care (MC) of High Care (HC), afhankelijk van het voorspelde indi-
viduele risico om een recidief te ontwikkelen. Naderhand werd recidiefkans-geleide 
zorg vergeleken met de gebruikelijke zorg (CAU) met betrekking tot zwangerschapsge-
relateerde zorgkosten en maatschappelijke kosten (zoals ziekteverzuim, informele 
zorg) en gezondheidsuitkomsten bij moeder en kind en werd de patiënttevredenheid 
met recidiefkans-geleide zorg onderzocht. 
 
Hoofdstuk 2 geeft een gedetailleerde beschrijving van de opzet en uitvoering van de 
studie. De PreCare-studie hanteert een zogenaamd before-after design, waarin zwan-
gerschapsuitkomsten en kosten worden vergeleken tussen de gebruikelijke zorg en 
recidiefkans-geleide zorg. In het kader van de gebruikelijke zorg wordt gynaecologen 
gevraagd om de patiënten te behandelen zoals gebruikelijk. Recidiefkans-geleide zorg 
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bestaat uit twee zorgvarianten passend bij het risico op herhaling van preëclampsie of 
HELLP, namelijk MC bestaande uit 9-11 polibezoeken, en HC bestaande uit 14-16 poli-
bezoeken plus eventuele additionele diagnostiek. Voor de economische evaluatie met 
een tijdshorizon van een jaar (begin van de zwangerschap tot 3 maanden na de beval-
ling) worden twee incrementele kosteneffectiviteitsratio’s berekend, waarin de kosten 
per QALY (voor kwaliteit gecorrigeerde levensjaren) en de kosten per voorkomen na-
delige neonatale uitkomst (NICU-opname en/of dood) worden vergeleken. 
 
In hoofdstuk 3 wordt het zorggebruik in termen van diagnostische testen, polibezoe-
ken, opnames, bevallingen en daaraan gerelateerde kosten beschreven binnen een 
cohort zwangere vrouwen. Deze vrouwen hadden een vorige zwangerschap gehad die 
gecompliceerd werd door preëclampsie of HELLP-syndroom en werden in het verleden 
behandeld volgens de gebruikelijke zorg. Dit hoofdstuk laat ook zien hoe dit zorgge-
bruik samenhangt met zwangerschapsuitkomsten. De analyse was gericht op de uit-
komsten en kosten van de moeder vanaf het begin van de zwangerschap tot en met de 
bevalling, omdat de zorg voor het kind geen deel uit maakt van de zorg door de gynae-
coloog. De gemiddelde ziekenhuiskosten per patiënt bedroegen €8.047, met als be-
langrijkste kostencomponent opnames en polikliniekbezoeken (samen verantwoorde-
lijk voor meer dan 80% van de totale kosten). Kosten waren vooral hoog in geval van 
vroeggeboorte en/of een recidief preëclampsie of HELLP-syndroom. De praktijkvariatie 
binnen de gebruikelijke zorg bleek aanzienlijk. Het aantal polibezoeken varieerde van 5 
tot 37. Hoewel meervoudige regressieanalyses aantoonden dat er een verband is tus-
sen sommige zwangerschapsuitkomsten en ziekenhuiskosten, blijft het merendeel van 
de spreiding onverklaard. Een deel van de spreiding wordt mogelijk verklaard door 
variabelen die niet gemeten zijn in de PreCare studie, zoals patiëntvoorkeuren, voor-
keuren en routine van de dokter of lokaal ziekenhuisbeleid. Dit kan er op wijzen dat de 
zorg voor deze patiëntengroep kan worden verbeterd door het ontwikkelen van een 
klinische praktijk-richtlijn. 
 
Hoofdstuk 4 presenteert de economische evaluatie waarin recidiefkans-geleide zorg 
vergeleken werd met de gebruikelijke zorg op het gebied van kosten, effecten en kos-
teneffectiviteit. Uikomsten werden uitgedrukt in kosten per QALY (vanuit een maat-
schappelijk perspectief) en kosten per voorkomen nadelige neonatale uitkomst (vanuit 
ziekenhuis perspectief). Vanuit het maatschappelijk perspectief lieten resultaten zien 
dat RGC niet kosteneffectief was in vergelijking met de gebruikelijke zorg door hogere 
kosten en lagere QALY’s in de recidiefkans-geleide zorg-groep. Bootstrapanalyses 
toonden aan dat de effectiviteit consistent lager was in de recidiefkans-geleide zorg-
groep (99% van de replicaties) met hogere maatschappelijke kosten voor recidiefkans-
geleide zorg in ongeveer 80% van de replicaties. Vanuit het ziekenhuis perspectief 
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bleek dat recidiefkans-geleide zorg juist kosteneffectief was in vergelijking met de 
gebruikelijke zorg, voornamelijk door lagere ziekenhuiskosten. Sensitiviteits- en sub-
groepanalyses lieten zien dat de resultaten robuust waren. 
 
Hoofdstuk 5 beschrijft de mate van tevredenheid van patiënten in de recidiefkans-
geleide zorg-groep, welke factoren hebben bijgedragen aan tevredenheid en of tevre-
denheid van invloed was op de naleving van de HC en MC protocollen in de PreCare 
studie. Tevredenheidsscores werden verzameld bij inclusie en 10 dagen na de bevalling 
met de Nederlandse versie van Ware’s Patiënt Tevredenheidsvragenlijst, de PSQ III. 
Scores waren hoog voor alle subschalen van de PSQ III, wat op een hoge tevredenheid 
duidt. Er werden geen betekenisvolle verschillen gevonden tussen HC- en MC-
patiënten. Echter, na correctie voor mogelijke verstorende factoren, bleken HC-
patiënten significant meer tevreden over “tijd besteed met de dokter” dan MC-
patiënten. De verwachtingen, eerdere ervaringen, psychische gezondheidstoestand bij 
inclusie en ingedeeld worden in HC of MC hadden een significante invloed op tevre-
denheid. Alleen ”tevredenheid met communicatie” bleek een voorspeller te zijn voor 
de naleving van de protocollen. 
 
Hoofdstuk 6 biedt een literatuuroverzicht van de relatie tussen preëclampsie of HELLP-
syndroom en posttraumatische stress, angst- en depressieve klachten. Een systema-
tisch literatuuronderzoek werd uitgevoerd in PubMed en PsycInfo. Uit 267 resultaten 
werden uiteindelijk slechts 6 studies geschikt geacht om te includeren in de review. 
Een checklist werd gebruikt om de data-extractie te vergemakkelijken en de geschikt-
heid van de artikelen in het licht van onze onderzoeksvragen te evalueren. Studies 
over depressie (n=6) lieten positieve relaties zien tussen preëclampsie en HELLP syn-
droom en het vóórkomen van depressie of de ernst van de depressieve symptomen, 
maar in de helft van de studies waren de associaties niet statistisch significant. Studies 
over angst (n=2) toonden hogere scores met betrekking tot de ernst, maar alle associa-
ties waren statistisch niet significant. Studies over posttraumatische stress beschreven 
in het algemeen een hoger vóórkomen en ernstigere symptomen, maar weer waren 
deze resultaten vaak niet statistisch significant. Concluderend, hoewel de gerappor-
teerde relaties niet steeds statistisch significant waren, waren de meeste wel positief. 
Dit ondersteunt het beeld dat een doorgemaakte preëclampsie of HELLP-syndroom 
mogelijk effect heeft op het ontstaan van diverse vormen van psychopathologie. 
 
Hoofdstuk 7 levert ten slotte een samenvatting en een algemene discussie over het 
onderzoek dat in dit proefschrift is beschreven.  
 Een belangrijk aandachtsgebied voor toekomstig onderzoek is het ontwikkelen 
van een verbeterd predictiemodel om vervolgens te onderzoeken of een aangepaste 
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vorm van recidiefkans-geleide zorg kosteneffectief is ten opzichte van de gebruikelijke 
zorg. Aandacht voor mogelijke psychopathologie mag hierbij zeker niet ontbreken. 
Vanwege hoge kosten buiten het ziekenhuis in de huidige vorm van recidiefkans-
geleide zorg, zouden toekomstige protocollen ook betrekking moeten hebben op de 
zorg buiten het ziekenhuis. 
 Idealiter zouden procesevaluaties voortaan moeten worden uitgevoerd binnen 
studies, om na te gaan wat de ervaringen zijn van alle betrokkenen (zowel artsen als 
patiënten) en wat de succesfactoren en knelpunten zijn. Dit zou aan de nieuwe vorm 
van recidiefkans-geleide zorg gekoppeld kunnen worden. 
 Voor de clinicus is het belangrijk om alert te zijn op de eventuele ontwikkeling van 
psychopathologie, omdat preventie en tijdige herkenning kosten kunnen besparen en 
kwaliteit van leven en patiënttevredenheid kunnen verhogen. 
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Valorization of research 
Over the last decade there is an ongoing debate about the societal impact and utiliza-
tion of academic research. This is also called ‘valorization of knowledge’ and can be 
defined as “the process of value-creation out of knowledge, by making this knowledge 
suitable and available for economic or societal utilization and to translate this into 
high-potential products, services, processes and industrial activity” (adapted definition 
based on the National Valorisation Committee 2011:8). In the Netherlands, the stand-
ard of scientific research is high. However, this scientific knowledge is underutilized in 
practice. For example, only a limited number of scientific discoveries find their way to 
the market. 
 Apart from commercializing the new intervention through a spin-off company, 
patent, or license, there are many ways to make impact, for example through the 
transfer of knowledge to health care organizations, by making knowledge and exper-
tise available for other organizations and by communicating knowledge to the general 
public.  
 A better utilization of knowledge (based on study results) is a valuable resource 
for the development of the economy and innovative capacity.  
There is a growing focus on utilization of knowledge and scientific results, reflected by 
the policies within academia and knowledge institutes and important criteria against 
which publicly funded projects are judged. 
 Currently, our society faces big challenges in health care. The population is ageing 
and will increasingly face dangerous diseases like cancer and serious chronic diseases 
like diabetes. As a result, both a further improvement of our health care system and a 
severe reduction of costs are needed. To accomplish this, major innovations in tools 
for treatment and monitoring are required. 
The PreCare study 
Worldwide, preeclampsia (PE) and HELLP syndrome are one of the main causes of 
maternal and fetal mortality and morbidity (1, 2). Currently, the Dutch trends in ma-
ternal morbidity due to PE are a reason for great concern (3). It is thought that a high 
degree of maternal morbidity and mortality due to PE and HELLP syndrome result from 
suboptimal or insufficient treatment (4).  
 Pregnant women who had PE/HELLP in their previous pregnancy are at increased 
risk of developing a recurrence. At this moment, there is no clinical practice guideline 
for prenatal care for these women. This lack of a standardized guideline was the most 
important motive to set up the PreCare study.  
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In the PreCare study, we developed a prediction model to identify women at really low 
risk of recurrence. Based on this model, women received either protocolized Medium 
Care or High Care, depending on their predicted risk. Medium Care and High Care to-
gether were called recurrence risk guided care (RGC). We compared RGC with care-as-
usual (CAU) for societal costs (health care and outside health care), quality of life, pa-
tient satisfaction and adverse maternal and neonatal outcomes. In addition to report-
ing on the PreCare study, we reviewed the literature about mental health problems 
among women with a history of PE/HELLP. 
Relevance 
The results of our study were somewhat disappointing, as CAU was preferred over RGC 
from the societal perspective in the cost-effectiveness analysis. For society, it is there-
fore not worth to introduce RGC into clinical practice yet. Nevertheless, for several 
reasons, our study is of scientific, economic and societal relevance.  
 Firstly, it is of scientific relevance since it leads to increased knowledge on the 
clinical, psychological and economic aspects of pregnancy care for women with a pre-
vious preeclamptic pregnancy. Furthermore, this study shows the gaps in current 
knowledge so that research activities can be prioritized. Evidence from the systematic 
review suggested that a history of PE/HELLP predisposes to subsequent development 
of various forms of psychopathology. However, further prospective studies are needed 
to confirm this view.  
 Despite considerable efforts to promote maximum compliance of the participating 
gynecologists with our protocols, adherence to the MC and HC protocols was poor. 
Unfortunately, the reasons were unclear since a process evaluation was not planned in 
the PreCare study. Therefore, we can recommend that process evaluations, in which 
the views of the participants are examined, should always be incorporated in future 
studies on health care quality improvements. 
 Additionally, this study is of economic relevance as it showed that there is a con-
siderable (unnecessary and unwarranted) practice variation in CAU. Current care for 
pregnant women with a history of PE/HELLP is probably not efficient. Introducing 
standardized care (through clinical practice guidelines or protocols) is one strategy to 
decrease practice variation by providing the best available research evidence in the 
form of optimal care recommendations. Introducing guidelines can lead to significant 
cost reductions and unnecessary medical treatments. In general, about 20-25 percent 
of the care provided is not needed or potentially harmful (5). Our study demonstrated 
that practice variation in CAU could not be explained by women’s characteristics or 
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pregnancy outcomes. This indicates that there is room for improvement. Further re-
search can make clear how costs can be reduced.  
 Finally, this study is of societal relevance since guideline implementation may lead 
to significant reductions in complications and medical errors. Quality of care received 
by pregnant women whose previous pregnancy was complicated by PE/HELLP can 
further be improved since this study has shown that attention should be paid to post-
traumatic stress, anxiety and depression.  
Schedule and implementation 
Based on the results of this thesis, it is too early to develop clinical practice guidelines 
and implement them into clinical practice yet. 
 Because of disappointing study results and poor guideline adherence, it is neces-
sary to perform a process evaluation concerning the PreCare study. Process evalua-
tions within cost-effectiveness analyses explore the implementation, receipt and set-
ting of a new intervention and help in the interpretation of the outcome results (6). 
They examine the views of participants, study how the intervention is implemented 
and investigate contextual factors that affect the intervention. More importantly, they 
can provide valuable insight into why an intervention fails or has unexpected conse-
quences (7). Several methods can be used to collect process data, including question-
naire surveys, focus groups, interviews, researcher observations, and structured field 
notes. These will provide insights into possible barriers and facilitators for and satisfac-
tion with the guidelines. Our results suggested that the lower cost-effectiveness in RGC 
relative to CAU (societal perspective) may be explained by a restricted number in out-
patient visits in the MC protocol, reflected in lower patient satisfaction scores and 
higher costs outside the hospital among the MC group. Patients’ experiences with 
these elements should therefore be measured.  
 A logical next step would be to develop a prediction model performing adequately 
in differentiating women according to their recurrence risk. The model we developed 
may be used as starting point that needs to be developed further to increase predic-
tive performance. To do so, it might be updated with promising predictor variables 
that independently contribute to the model’s discriminative ability and calibration 
measures, such as maternal thrombophilia and high-density lipoprotein (HDL) choles-
terol (8, 9). Nevertheless, we must realize that it will be difficult at present to develop 
a robust prediction model because of the heterogeneous clinical presentation of PE 
and HELLP and their incompletely unraveled pathophysiology. Furthermore, prediction 
models tend to perform better on data on which the model was constructed (deriva-
tion set) than the same model on new data (validation set). 
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Subsequently, based on the results of previous steps, a new guideline can be devel-
oped. Attention to possible development of psychopathology should be incorporated 
in the new guideline. For various reasons, however, guidelines have proven difficult to 
implement. The new guideline preferably is pilot tested before implementation and an 
inventory of the barriers and facilitators for adherence to the guideline is made. Barri-
ers can arise at different stages in the health care system at the level of the individual 
gynecologist (i.e. lack of knowledge or skills, resistance against working with guide-
lines), of the team (i.e. lack of knowledge or skills, insufficient collaboration), of the 
patient (i.e. unwillingness, difficult guideline adherence for some patient groups), of 
the organization (i.e. lack of registration/information systems, time restriction for 
adequate care), and of the wider environment (i.e. lack of financial incentives, misuse 
of guideline in medical disciplinary law) and of the guideline itself (i.e. doubting evi-
dence of the guideline, poor layout, unclear decision tree, unclear content).  
 The implementation strategy will be based on the barriers and facilitators from 
the previous step. Ideally, guidelines are developed to be disseminated and imple-
mented in such a way that gynecologists and patients become aware of them and use 
them. Guidelines do not implement themselves; they need to be implemented active-
ly. Well designed strategies are needed to optimize their success. 
 The protocols should be disseminated via various channels, both written and per-
sonal. The Dutch consortium for women’s health and reproductive studies could facili-
tate publication of both the development process and the availability of the protocols. 
The protocols should be published in scientific journals and on the internet. Clinical 
leaders can be contacted to promote the protocols, because highly regarded individu-
als influence the practice of their peers. They can deal with misconceptions about 
guidelines and help clinicians observe the outcome of a particular innovation. Remind-
er systems should be incorporated in gynecologists’ daily work, such as computerized 
prompting and mailed reminder systems. These reminders can be acted on immediate-
ly. Publicizing adherence to guidelines may improve public image, sending messages of 
commitment to excellence and quality. Feedback on compliance with the protocols can 
promote good will and potential support. 
 Strategies described above are probably more effective when used in combina-
tion. It is however important to notice that more research into the details of different 
implementation activities is needed to understand the critical determinants of change 
in clinical practice. 
 In summary, a process evaluation concerning the PreCare study should be per-
formed. Next, a new prediction model should be developed with a better predictive 
performance. Based on the results of previous steps, a new guideline can be devel-
oped, incorporating attention to possible development of psychopathology. Finally, 
this guideline can be disseminated and implemented.   
 133
References 
1. Chhabra S, Kakani A. Maternal mortality due to eclamptic and non-eclamptic hypertensive disorders: a 
challenge. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and 
Gynaecology. 2007 Jan;27(1):25-9. 
2. Moodley J. Maternal deaths associated with hypertensive disorders of pregnancy: a population-based 
study. Hypertension in pregnancy : official journal of the International Society for the Study of 
Hypertension in Pregnancy. 2004;23(3):247-56. 
3. Schutte JM. Safe pregnancy in the Netherlands. NTOG. 2010;123:27-8. 
4. Schutte JM, Schuitemaker NW, van Roosmalen J, Steegers EA, Dutch Maternal Mortality C. Substandard 
care in maternal mortality due to hypertensive disease in pregnancy in the Netherlands. BJOG : an 
international journal of obstetrics and gynaecology. 2008 May;115(6):732-6. 
5. Richard G, Jeremy G. From best evidence to best practice: effective implementation of change in 
patients' care. Lancet. 2003;362:1225-30. 
6. Oakley A, Strange V, Bonell C, Allen E, Stephenson J, Team RS. Process evaluation in randomised 
controlled trials of complex interventions. BMJ. 2006 Feb 18;332(7538):413-6. 
7. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, et al. Developing and evaluating 
complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655. 
8. Facchinetti F, Marozio L, Frusca T, Grandone E, Venturini P, Tiscia GL, et al. Maternal thrombophilia and 
the risk of recurrence of preeclampsia. American journal of obstetrics and gynecology. 2009 
Jan;200(1):46 e1-5. 
9. Sep SJ, Smits LJ, Prins MH, Spaanderman ME, Peeters LL. Simple prepregnant prediction rule for 
recurrent early-onset hypertensive disease in pregnancy. Reprod Sci. 2009 Jan;16(1):80-7. 
 
  

 135
 
 
Dankwoord 
  
 136 
  
 137
In mijn studietijd had ik niet gedacht dat het zover zou komen, maar toch ligt hier na 
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instelling toen de inclusie in het begin en de data-invoer op het eind niet helemaal liep 
zoals verwacht. 
 Beste Carmen, mijn dank gaat misschien wel het meest uit naar jou. Dank je voor 
het feit dat je me deze mogelijkheid hebt geboden. In de afgelopen jaren heb je het 
steeds drukker gekregen, toch kon ik altijd bij je terecht wanneer ik vragen had. Als jij 
er niet was geweest, dan had ik nu waarschijnlijk nog zitten zwoegen op de laatste 
loodjes. 
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van de vele besprekingen en je beoordeling van mijn stukken. Bedankt voor je verfris-
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 Beste Sander, jij bent mijn medepromovendus. Ik heb bijzonder veel plezier be-
leefd aan onze samenwerking. We hebben samen heel wat werk verzet en heel wat 
zorgen, files en syntaxen gedeeld. Ik heb je oprechte interesse in zowel privé als we-
tenschappelijke zaken altijd erg gewaardeerd. Nogmaals bedankt voor de prettige 
samenwerking en veel succes met je verdere carrière bij de GGD. 
 Mijn dank gaat ook uit naar dr. S.J.S. Sep, die aan de wieg stond van het PreCare 
project. Beste Simone, jij hebt het mede mogelijk gemaakt dat dit project er kwam 
door mee te denken over en mee te schrijven aan de subsidieaanvraag. Bedankt daar-
voor. 
 De leden van mijn beoordelingscommissie prof. dr. S.M.A.A. Evers, prof. dr. J.G. 
Nijhuis, prof. dr. M.H. Prins, prof. dr. I.M. Engelhard en dr. A. Kwee wil ik hartelijk dan-
ken voor de bereidheid om mijn proefschrift kritisch te lezen en op wetenschappelijke 
waarde te beoordelen. 
 Graag wil ik alle gynaecologen en arts-assistenten bedanken uit de participerende 
ziekenhuizen: Academisch Ziekenhuis Maastricht, St. Radboud Ziekenhuis Nijmegen, 
Isala Klinieken Zwolle, Erasmus Medisch Centrum Rotterdam, Academisch Medisch 
Centrum Amsterdam, Onze Lieve Vrouwe Gasthuis Amsterdam, Universitair Medisch 
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Centrum Utrecht, Maxima Medisch Centrum Veldhoven, Universitair Medisch Centrum 
Groningen, Amphia Ziekenhuis Breda, Atrium Medisch Centrum Heerlen en Kennemer 
Gasthuis Haarlem. Hartelijk dank voor jullie medewerking. Jullie hebben jarenlang 
meegewerkt aan de (soms moeizame) inclusie voor de studie en de bijbehorende fol-
low-up. 
 Mijn dank gaat verder uit naar alle researchverloskundigen en –verpleegkundigen 
van de participerende ziekenhuizen voor hun grandioze en onuitputtelijke inzet. Corine 
Verhoeven, Jannet Bakker, Gerard Zijderveld, Joke van Rhee, Titia Winter, Diana Lutjes, 
José Keurentjes, Lida Ulkeman, David Borman, Maartje de Reus, Jolanda Willems-
Robberts, Nathalie Teeuwen-Dedroog, Sabine Logtenberg, Birgit van der Goes, Joyce 
Cantineau: hartelijk dank voor het includeren van patiënten en het invoeren van alle 
data. 
 Zonder het Verloskundig Consortium was deze multicenter studie niet van de 
grond gekomen. Ik voel me ontzettend vereerd dat ik deel heb uit mogen maken van 
dit krachtige samenwerkingsverband van Nederlandse bodem. Ik wil de arts-
onderzoekers graag bedanken voor de goede samenwerking, de gezelligheid en de 
gedachtewisselingen tijdens onze driemaandelijkse bijeenkomsten in Utrecht. 
 De leden van de PreCare projectgroep (dr. L.C.J. Scheepers, dr. M.A. Oudijk, dr. J.J. 
Duvekot, dr. M.G. van Pampus, dr. W. Ganzevoort, prof. dr. M.E. Spaanderman, prof. 
dr. H.W. Bruinse, dr. L.D. de Wit-Zuurendonk, prof. dr. J.A.M. van der Post, dr. J. van 
Eyck, dr. M.A.B.H.M. van der Hoeven) wil ik graag bedanken voor de prettige samen-
werking. 
 Een groot woord van dank aan alle destijds zwangere vrouwen die vrijwillig en 
belangeloos hebben deelgenomen aan dit onderzoek en veel vragenlijsten voor ons 
hebben ingevuld. Vrouwen uit alle windstreken, van Groningen tot Maastricht, waren 
bereid om dit allemaal te ondergaan. Zonder hun trouwe participatie was deze studie 
niet geslaagd. 
Ik wil graag alle ex-collega’s van KEMTA en ook de leden van de MTA-groep in Maas-
tricht bedanken voor het altijd kunnen stellen van vragen, het delen van jullie fantasti-
sche kennis en voor de gezellige en inspirerende werkomgeving. Zonder jullie waren de 
afgelopen jaren niet zo leuk en leerzaam geweest. Beste Thea, heel erg bedankt voor 
je hulp bij bootstrappen in Excel. Ik heb veel geleerd van jouw geduldige uitleg, input 
en inspiratie. 
 In het bijzonder bedank ik mijn kamergenootjes Iris, Mirjam, Annemieke, Sanne en 
Bram. Het is erg fijn geweest om jullie in de buurt te hebben als klankbord en lotge-
noot. Bedankt voor jullie waardevolle adviezen en oprechte interesse. Ik hoop dat we 
nog lang contact zullen houden. 
 Dan wil ik ook nog graag iedereen bedanken die mij op minder directe wijze heeft 
gesteund door er gewoon te zijn. 
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